var title_f32_51_33584="Moxifloxacin: Drug information";
var content_f32_51_33584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Moxifloxacin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=see_link\">",
"       Moxifloxacin (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/29/21976?source=see_link\">",
"       Moxifloxacin (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10311 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33584=[""].join("\n");
var outline_f32_51_33584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/10/18595?source=related_link\">",
"      Moxifloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/29/21976?source=related_link\">",
"      Moxifloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33585="Nail psoriasis oil drop";
var content_f32_51_33585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oil drop sign and distal onycholysis in psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1BSNozIPqRip4LiLy9szFlB4C9vWqxizhcAD196a0ZDYZiCPQV5J9Fyp7ktzNASfLickcfe4rIuDKx2BlU9R3q9I2FPzYzwSRVcqpcEPtycfMOPzqtyoxUdimnmJJll3EHq1WLeOQTu5KhVOSOuTV39yyBWRVffyy8jFMDRxsOmNx4HX/APVRYUpkE6nJlARQ5wAOT0qpfRmG3O0SMp79ea0po0eaMgooOWIz06YzUl1EktvsiIdycAFsDr6VT1I5krGbF5booyyZA3cHn61JE0ZTazBnUkYPORS29vHGieZJkdME9Kc8KxzB1BIHXbQtCuZNlaVGa2laNCdp9eRXH+JFZ7SXcOME12EZKGQANtPYH3rn9ZR0MnmAFGjJwe4pPU1p6M8JnmOna/b3AyBHKMj26V9O+E7tbyC2KZYNjkdPxr5p8awbJiwGMYI/OvcfhPeK3hy2lYEuyjBzyB7VnSVtDpxfvQ5j0+5nK3DAZXt9PrUEu+dHwSVKkZz1pimSZhzkkA8jqamuFaK1DA/vEOTWp5a92xR1CEx6LbKoBYEk8dqxbm4R7FAyFpFG3d6elaWrTF9IilXKjzG/l0rl5bgZCg/KW5pSZ1UINx17k/8Aq5Vwc/LzSzDynw5BJ9KgkKi5ftg+tQmV3YjG4diKg6eUnlbnjpVSS5IlBB5HftUkiSvyo47EVB9nkLfMvTk0rjVupp2t8p+YHJ6FSal+2gEgbgnYbuhrLCmMZ2gHPcVVuJGXk55OKr2hm6akzYnuwx2rnLCq88/mIq+h5BrKjuCZcNyB0qx5o3IcYGaalcTpJFu5wpyn3fbisy9b91JwOgNX5CCAOTxWffcxsvpxQwSPILxfK1+7UYwZTivSvh9JtbYVySMZ3YArzbUwf+EhucnBLj8OK9A8Ao7XqADjAJ9TWFL4zpqq9I9btZHth0+9+7A9MjrWzNh7ZhCWKpg4bPFZUcC7rfy/kJk3EZz0FaccrQ6iIpflWVSM9jXazx5q7uiiZNrRO5G1uoB7VBMV4KZA7Uy/IjLiTOR0PYiqL3AKK/fup6VmdEKfNqXZtrfOo2/L+oqtKoKow6Bex6Gq0dwcn58qeCD2zU8O6FvmG3JxgjjmkU4uBOYRLAjYJLv1/D/61VpFQSHGSRxk9R9auMm2G4UZV4zvAzyKo3rAT71wVkAYketOxmrvQrllweQP0NNuJ9pEbIjLjNJOPkJwNp4zjpUV02HVwVOOCNmfapuaxRLICwxDySMbHwe3rWfb7iynG5VyQRzgVajdmhZMlXHbtzRbJst5w4AwpPzHt2o3HexzupSCKGTLHgEqO9eb6Y/2vxJcMxyPMwPwrvPEDNBbzM5XHIH4da8/8Dk3OpPL/ekJ/WsZ7o7KC0b8j3Xw1EqWq7OfU10Mch3HKquc4cdRWJoSIIlEnTHPbFbyfJnYP3THAOa6TzKm5XkRVlyfvkbcgdfwpHY8lQCeuKR3KgxONozwfT/61JE4DFHIDN/F2pDt1FkbemM89fxqJmKquFIzwc+vrULShWIOM9KeriRST0UZNMXKxEcNyRknsTg1U3SKPkQOh6j29c1oQKst3GhO0twAfXoKRoGMVyG27gpHA6kc0Et8pmMQz/PkgjgHt7H8apHMe7+J8nAznJ9q1VWAsp3suF4IOcmoLaJCwZ2DSMc9eRQWpWOh3sEDMCA3DZ4I96gdtrk9QD3p1zMGKEMVdzhlxxTSAc4GccY96gpeYy6xM2FIT5c/l2rPljCJ1yAcFu4rRV0BORuz1xVW5G4gZ4/SgtNrQW3byY0xzuyGU81KqxyRoW+XHHPeqz5O1yigjqfanyYGQTgqMjPc0zOUb7E8sSRjzQFcDGST09qiDeZJ5kaLtUjIwMHmoxO0dsYZQQznKg85z/SprYeVMkUyjABKnO3IoJaaLboHhaVUTcOSFHHtVScjySy8EcHjBBq40jKmY/mDZG1hgjHvWZeedCDJKhETMcZPNNkRWupTY5lUbWwffrWbqz7kj3jkAqeO3rV5ifPRmIwvXFVb+NZYNqYyPwyaR0x0PFfH8JEa8YbJ6+ld/wDBW5+06PCpICQKFx71yvxAt828kjKR/D9DW18DZPJ0OcHlnmP6YxURVmdMtadz33ScvGWdiSDT7xfMhnXOM5Gce1LpOEtE5ycc59ai1GQIWxw23OPbvW9tDyt5mBcSltACEj5JSMH6VyUnzzhU+8WziujuHA068jB5DqwNYGlo0l0xJxisJ7pI9Oj7ikyWG3d5yGJyPWte0s0jPzDJPFa0VvayqZYIisj9UJ6VYa3XAHyhsAkDk1caZx1MS3sZ8dsmAGIA+lWl023ZlwSS1HkrG5DI7H64q0vmpIPLCLgemcVpGn3OaVSXcrPoXmMyxnPfkVmav4fYDC4fjJJGK61bZ2iDknOf4O1YuqwzwyEeZIIzn73en7JW2JhXmpbnnd7ZTWlwTt/+tUcUmV+c7SK6bUlYfcYOR1GORWBOFuZZNibJgMkDufasJU+V6HqU67mtR8UyyY28HFR3anyHNV03RLnvnJ56Vek2yWZ6cClHzLemp4trBYeI7wHqJBXpPgHJcsDgqgP61554ijKeJbwYxypx+Fd74EdgrbAf9Xzmsqb981q/wT1yKZTJC6cBFAwO5/8A1U/U5SjwzhSyZ7mmWlsUtCqt8qgNn6itW7US20SFQy7sHjiu17HlpqLMHUZlmCsGwOmD1FUcLs+vQYrQ1Ky2b9ucqazBuj65x646Vkztp2a0I2XB35Bwc49a1oJC8iJNkxsAoOe1ZIkYN93cB0x0qR7qVVQBCQp/OpUhTTlodZcQfZ7tTuRkcffbnI44rF1LTzaq6u6MwJPHHFTx3xubIQytzkDd3HuKh1a6WePc+N4GxuepA61pdHHGMlKzM9zm3Kt07etRmMsiYyGJPvT1ZSSVyFXr7UpjYTKqEblyTz6CoN3oKqCOFCYxgDqB3+tZNyxFtO0hBUMBnqa11JMahxgsf8msi9cea8R2lRzkDGRSYQOF8c3flaY+5iMIQPSuc+GcJMqPjn0q38VrnZAsWeJBgfnVr4cW21EbkVlJao76XwN+R7BprKAA+SDWjHdBSFOAp7EZrLsSuwEgBu2aR5zknIx3JrovY4/Z3LF3dFpcBVB6ZqCZgqjBJz0xVZZQ/Pdf4vWp4h5nXP5dalyKcEkRrIzzqfujv6VPaSqI5VfaHODz6Z/wps8LKNxUc9j/ACpVg+UuQQAnrmlzWJbi0a1pGstxE33hgAEdPqDSaiZULRxnPzHLZ9eOahtpd8KlWAMSYUdMZP8AP/GtHW0hjWKaM/K+FA/Dr+tWnc5ZfFYwiI5LaOHgyMiqM8c5qNt3nx+XmOVPfnNOiMam1ZxuKMFK9BgHjn8KltmINxIw+YHgnoD14PrzTLkrIvMGjnYXAG3+LOc/UVMpEkY3EbUJG/8AvCmmRmnwVYyL0yOD6iljGJsqCI36Dj8aguRVIeF3GdynkfTFRLks27BXtirzqocBOSynOe2Ky0Ia5IdgqgZxng0bFLXUaryTbwBkAYyKnIX7MM8NnIz3HpVJ5QmcD5Sc1fEYLBo8ARorHJ4OapDaBIZWECB+DnaT7e9aF1ZmKaOVXE7RjJDDqPbFQLG011DGzFTkNuU5/StWGWdpZMgPEjgFgMZ6g00rnPUk+gyBptQLNFCoTnBY4ArJ1c5BhM3mup6Y/UVrzCRHa8tQArHa8XIBWsjU1RTvRHDN1z1+lNoyhqzEwUhAOfMVsYNNny4cIoySWBPpVmF/OLKcDk9RzmkKghdn94qealbnVzdDzDx4C9g67RgfNux6jpWZ8G7sx372oPIkJ+ldP45tsWEi7c+b936g1wXwzYxeLJUXn5MgevIrN/EdlL3oWPqnQ286PLAYztFQ62THx0x1x6Z5pPDrYjyYyQe9V9YlwGJ5BGVx9a3T0PO5f3uhz1wS0cu1jtLVa0+OD7CsOwG5kk5AHLD61RvJRDE46fN+uKueDYXuDJcyfPvJC7scDPaoSvI6qukLnSWdkR87ttQHhVHX61ae3QZCqB7YqSIctg5Hr609s4PPUV0JJHlSu3cyTFtkbnpVpB1Kj05702QbZeelLF0YHnHQii5TV0alvc+XbspGTWPq87TCMS9FORgVeiYncMc47VS1JDheO9O5lCNmc/fJmXcDwa5jXbaWI/aIM7lO7gda7O+iIKEDqPSsu4TcrDPy9OKUoqSsdlKfI7nJyTLexCWLmQ48znnPpVyLd9nzggMMde9ZkiHS9ddACIJ/mHpmteZVVV2ncpGR71yW1O+T0VtjyXxRGx8U3I7ugI/Kuv8Ah8SXgi/ikwv61g+J7c/8JLI/ONg7/Wug8D4hMEqnEqvkE9AMelYwT5zabXsrHuKRxoQkQA3kZA4wAOavXzwpARvAKjlT61zEOsR7IdjgsiAk9cAdfzJFXU33JS4upAqnkbsDj+tdjkeLKDTux0x80EkE5+U/hWbc2spboRx6dq0VfbxGoZf7xo5kJwJXc/3cAVLi2aKty7GL9kILYxnvgVHLCxIyOAM4FbqTSwysJY2zjpgU5/s06qGXy3GMnpS9kwWIaepzgyo9D3NQyXJYSJ1BGc59DWrqNntaRoyrRrz74rE8vbOS2cH8qhxaOinNSHgHzMEjcOelPSXG0AcszGnxLu3MeAMZ+hqFEUSgE9zj86C5alqZEXfJEclMArn19Kx75T5iMo7YA+laZzkZIUA9fWs2+yiA56HORTauTHQ8f+KjM+sWEBz0LV1vgO3McCfKcYzn1rkPHhN14yt1A+7Fnj3OK9P8JWPk2MbE8duKzesrHfH3aV31OijfbGc5B6+tQO/mShRwec8dKkcMVbGQVPPsKXTLZri7CHIODg46A960tfQzuoxux1jCXbAzjPTGK2reGCBSAwz3qOIRrMU09DIqnHm4wP8A69aVtZPHE0jFGHXBHBP0q407nBWq83oUf3Eh3E/IPz+uDSNbZVm27R6gZBoa3DTIfl+Y84BAq+lrKihWO1T0NV7LuYylYw3iMSyOm0tgEY9fQVoPKLjR1BIEytkc+lZt/cfZrhbe4ziQ4Rz0z6GgObZkJwFK/wD1qi1nY3SclqRWsYdj5n3C2DgdCc9P0/OrFlvFozKq+VvJwx5Pf+VVNOeQRPkhjvMma2FhMEEMkhycDkfdI6DiqiFV20ZNeRsGyWG/O0n+RqLzt8PBHm8jI9feptTIVdm3Lnj9aowKIYjL0ck4PrWdtTSOsdR9wpXaVYluQSvSs2NVwC4BOcY7nrWuy+XabpFOSAVOfesYl0LSITweRjrQ9CoaiNhpNhB68cVchnjWOWOU7Rtx9axGnaJmI596ha6LEheWI6UuY0dJyOi0+5SO4Xc4yBwx7elaU3iS3t2iARliVhvP96uGWWRhtUYb+dJFpt1duURGYdcjsKaqdiZUIPWbPRLjxPbShFiiUq3Bz/jXN+INUDqEh6EgYJ4ql/ZkUEBSQTxMTgM56/8A1qz73S5/L8y1ZpAOSG6iqlJ2uZ0qVKL0LdnPCl4gY7g2VJB79jTxIFu9xyqnGTnoa5uN2WQfLtKnJya0Rcea2cgE8nNQp3OiVHqupS8ZRFo0x8y56jjrXl3gWUWvjqJS2PM3IMV6pqzl0B3A4YdTjODXj0so03xdazjjZcDOD2JqZfFdF0VaLifWWhHNkozt5LfUf5FJqEZkJ+U4O7Ax6CofD06S2IljTK7eO2RmreoSorM+QGQ/d+owK2voefqpnCeIV3LEqZVGY7jjpjj+tdd4XjC2KIn3FHy/41zer2krxJNjbHLOqY9sZrt9IhEdqigYwMfWin8TNcTP90kXQvBxSScIPU+tSADacdTUEpzGORxkda3PNW5UnO1wcD86ISpVxk9KhuTljzxT7bOSAeopGzWhbgPOc8YqWeBZbV33ZYDoOMVUT5gMHp71KZUWxlBJ3/n3qrGDRlXUR8kc8jisqYAHOK25hvjHrnpWZc8E9uehoNYnL+KbIvAsqZDJ8wx61Hpime2UtyQPyrevUWS3KnHNYNnGYzJgEKh5IPSueoveudkal6djjfFFuP7Zc8cxj+ZqtpLtb4RSQTjoeRWz4hVX1MODldnUjpzWRMfsm2TqwOF+prC1nc3hK+h6B4fVY4Ve4dCWYYTPJx0zXa6bayTnzbnOCOF747VwHgpDIYrgg7zwG6/j9a9S09VESjbniuuCVrnn4luLshsUCx/KgwO+STmmSg7ySAT79BWiwGc9sVSc4ViSR1rTQ5Yt31KIX5nxnFXrfy3gYXAODwD6VVcqS3selSCTbboBySe4oujSUXYytUtCLtzbMwXAbB9Kw5JijrBeRnO4nep6fT1rpg4fzVaPGWwGHtXO61bNIrtESjgZBBqJRuro1pSs7MkjhxI6jCh1z7dcioYlbJOOAO/uaPDt2L+3MLjFxCSmMdeP/rVJGCvnHrgIAT7mud9zpjdNqRBdDbEcsQy8isjUpB9jyfujg1uXjhQQuCT1NczrkgSwm+bAVc4HtQzSCueaXKfbfGa7QTtRR+ua9o0iAJaIFCg46ntXjvgtGvtfuJzyA2B6V7ZY5WAAZIxyDWdPVtnZiPdSj2JZQkFpNI4ygUFzjqT2pvh+zkkLTT7o2cfcBwEB7e5pl8ou5ILJN3lqRJMR39BXSWEAhjVQMEjt2rohG7ucFWfLCy3ZNFbJCgVVAA4GOlSzqI7RjgCnuccED3NV9QkAt1DHFbbHAryauVI1BkQcc98VrGYBVWVQ6AYxWXZyLJOqr27VdkJw/QnOMelOLHUi2zk/G0Mc9jMqrwB8px0NVNFuf7Q8NwSPzKgMbD0IOK0tZIbeDzweK5jwS5W51KyZjuSQOgx+dYz0kvM7qKvSflqaVrIfMCrwQa6azj+0QMZJFRUG4dhg9RXPeUYpm6jJzWjD5zQgKR5ecgEY29Dz7Uoqwq65ldFm8cvfBA2dnUjuap+afKORnawwfTPerMSsImkILM+WPrVB/ld152sMmpN4rSxN9odisTnKKCAax7242u3lNtX0rTZlxleuB+Nc3d/v7goFON55H8qmRpSirtiGVnyGyM/rV2w05rkkoMgDqw6VdsbBRIslypitXOMYweK0vMWaUQ2MLRwL0Y9W9zRGm5bmdSvbSJDBpMUXBZARz8pzW3YFIY38gxhj/E3YfSo0tkROSruevpUoWMxAhRnOMGto07Hn1Jue5VvdDt3jMk8zTSMN2Fbpmuav9JETrLYyzW0iDgq2cn6Guq37JCrAsWUgelYV1N87gk8etW4RfQdNzXU525uRc/utQjWC9Bwsyj5JD6GqbRywzFG5ccHBzWxqNuLyxaJ2K8jY2OVPrXL2U8n2tre4O6WPox/iX1rmnHlZ6dCd0zWkAlgKSKclh+ByK8e8dWzW+qSkjDRuf0NezTQnymJI64FeY/Ee1YzSSEcknNTJWSZdCV5WPa/hfq4vNEtzJwBGCPTpzXUagC6qmFCyjILd8cc1458G9Vb+xYE3cxtt+o969cvLhbm1jfd9044Oa0Wxy1oWqXWzKGp+fdG0LbUt4mOEXu3rW3Y3LpKqP0xxS2Vis+lz+WNzREOM/wCfapRDlFcDp3px0MHOMly9i6821QSRx6Vk3t6Ilyp4DEVPKzLG3fHINYt/uCS7j3z+dXKQUqKbFur8eWCDTtPvN8uC3Y8VgSsWVsZwpz+FSWk3lyoCTnFZ852PDx5TsoZVOwHHPBquLiPzpY5Tjad2RmsJbzeyqXZTUAuGFw3z8EYznrWnOcscM76m6kwktzKWOWc4GefxrOurkISNwOTVWAMEQEtuPOM1JNbmRPw44ocuw3SinqU5JzL1BxSaTG5vphFIEmC5TdyD6gjvVy0sSxPOT2UVDJDJYtJfPgeWp8tT3J/pUWe5M5R1jE4zXQzamRJgMR/Wua1OTzJYo3JY54GOAK6G8ea61WYhFkzjL5wFGM449PSuYtmebUgZc/fJAHQDPSsp+R0YeLb16HqPgyDZBFjvXo9pgRqoGMetcR4UQbI+B0HFdqtykTAbhkDpXVHRHBiPenoW2OFb6dqpTuChHGc4I6VBd3jRxO2OOvNVDdqY0G3G4FsmnzExpPcnJ4IUetSSABYlyc46CsZ9TUA9cAVJHqisNxOMDApcyNnSkuhZHJc8ADP51mXvVuw7VoQlXg3Bss1ULkHcT2z3q0zJRdzkYJW07xSrKcR3AwRmumGD9sU84249O9YHieHZJDcxg5jbPA5rZsnEiGY52yRjAxjpXO42bTO1NSipeQyYKQOTtPfFcZ4wm8rTLvnGEIAz1rsXTcDz+J9a87+JdwILC4XOGZeMVnPRaG1FXkkZ/wAIrXzbfznyNzE5xXsEEZVcAY6KRjArzT4T26x6JCz8lueOtevWkEb2DHOJDls4zgAZP9KKa0KxU7PUr6bF/pDkfdDYHufWt0skSlnIHFc7bzGBSB2GRx1/+vUj3Tz43t8orZSsjkqUnN36GnPfqcqgzisq8u3nb5ug7ClllAD92FUN+5up96TkyqdJLWxe08SG5jMfpkjpV0ySQuWZvlzzk9qbpeBJK+MlFx6dqLpHa0dsDHr261S2Im7vUz7tlkmOMHPtXIWrfZPGcp4HmIMAmuhjmJuSrHgelc54mDQ6taXEeAehPt1pTd1fsb0VaXJ3R0kkqmXOeVJyPUVbnmEdgzbTvUZFZkOLmJWQESYzz0Ix1pdQlZrVo8kDO38u1JsiUdkdJtOcAc4IPPAxWbdxsJ3+XgnAOOvFbwjGOhyMnHase/L7zu98D0qR03dlGbakXBO7oQKy40WKYyscEDK+5rSwTGc8jGAe9QB4RcIXGVhHA/vHHSpeps20mkXbbfczQPcMXOOVPRRW20aWmDC28sMcDGKyNL3Md8nLMcnI6Vs+XlF9a6IqyOCstbFeRWZumSRk4qWEfuOQPlPpU2wCMEnv2p0Sgq4HSquZ9CpOPmVsE81g3i4nkAzjNdNcRbkGMcVgagm24eka0+xnooHBJzXP63aywS/brRVaeEE4I4YY5FdMUxg9z3qC5i3Bl9Rg0mrqzNb8srmNaTpf2kUsTncyglWHQ+lcn46txPYu+AGyTx6VuxQyafdgpIotZWIKgfdI/lUPi6FTbOYgWQYww6E4rBq8WjWEuWa5Th/hRqQtdUnspCBuyUJHTIr3uwm3QwyvloXAzgdSPU+tfKyztpniNZlJAU9vrX0T4J1xLmwCqQVYZxn+LHb61MZbeZtVjzJ2Out9X/s+7NzE7+W/yyRsOCPT6+9dhAltq1st1YSYJHKeh9/SuTkhhu7cYTll4B7elQQNc6RtnsnKk8EdQcdiK0TtvsefWoqouaDtJfibd7HJEzCVWB6YIxWTcW3nRybWBwM8V0ul+IbTVFEVzGIbnH3X6N9DVl7S2d3TywNw7d6ej2MI150XyzjZo8/NkzKwAAyM81WFuVZQ3Tpk16C+kQsM8qR37Vm3GkJuw7huc0uU3jj09zg5EYXWBnr1qxbwf6Rlj19fWuxfQ7Rir5fJ7elRvo0Cvnv2oUWXLMItWRgwqvmOWOR2HpXR6bpxuoUCqVTHJpqwWNsNzqoI5OTTH8YWtovlW4WRxnAUdfxq1ZbnJUqzq6QRc+zwacG2kbgOWPauD1+/F1KwQ4iQnB/vH1qzqmsT36N5n7pCRlAc5H1rnr2UYIHTJxUzmrWRvhqEovmnuYsskVvompSNw/mhEYe46Vzml4F0mRyMVq+IJAumWsafclYyN3yQSBVPQbcySO+R8oPP4VzTb0R6WGiknJnqGg3AjESqRxxW/A7O5YkDHOa5Dw/jcGPQA44rpDN5QY7iTtNdKloc06dpWLc8oYbAzYB/Om3oXPsqYArO8/DEbs885q5ey72ODjjFJu4clnYrW9vvYccHrTZrUDciHk9j6VatQN23OfWmzMux34JLDA/OmlYbk7kcTNCCADx0pySGVPQ0yY7YDJyc5NUkujGgBOFI7+tWnYzlHm1QatE0tnKEI3Ac8dR0PHeq+jzBtJ2g/KcD6VNPchoTzhh3xWfp0kaRvCu7vkEYznkY/OlJptMIJ2aZpPKFQ5PA6k1478XrlljjUgjdxgn6V68qZTL/ACxIO/dq8L+LN15+rwxq2dvJrGS2RvTko3Z6P8LkP9hQDAwVyOP8+lenaK6XFw1sW/5ZHBPVc/8A6q84+GTkaBAFwMr1Pau8tN0MiTwsQ6gfl6GlT2KxEOZsfeWk1uSsin2I5B96pwpNI52qc9K6aw1GG8Yqfllx80TfzFWRaxySKAcE9BitUrnEsRKn7s1qclJaXJ3bV+8e5pslrNAimRMY6kc12H2FXfgjOcVDdWayq8bLgnijlJWM1MC0lcW08fG5yOa3EiDafsODxyaq/wBjTK4aORCvXk4rVtdOnMJTenI5IOcCmlYKlWD1TOCkhPmu6jnpWRqEXnXcazKcBt4JGduOen0r0KDRiJSGQH5u/pUF9pkUcrv5QAAOO5GQaHEr63FPQ5W1UR3EkMb+YoOAwXANQatKSrOxzu+9jselTzFI5Fy2FVRzjqMelY2pXQ2OxAXPPSpb0saJ8zueoRx/6KM53Bck/nWBqgJl4boOeO9bNnIXjAc57dfrWfqMTGSTcMRkDketIdK8ZWZkXTO7qIVGQOmetRi3y6RFeY1+b3Y02K6MeoqFX5VB3E+gq3pkiGV2kOWc5zUx1eptJOKL1ohUKMfrWjghCwHWordBlSuMd6ulB5W3JweprpOOTuRREeWVHFOiJZ5AMnio4Vw7KDwRU8B2zg+o20ENK5Wlz5QKjjNZeqxFfLlONsgPT1rb2ho3jI45INUdSQyaWHHWN8H05pFQdmjA6kCnOuaQDbx1I6e9SkApz1oTNZnNazauXATADEAg4x7Vn3L50Wa3kBDo+CMd66bVIg8ZAzyOtcndszNI7fxH5j6/Ws56bFp3SZ434pg8vU2OCK6f4a+IPs8y2lw3yjpn09fwrK8cwhbxXXpzXKxSyW0ySxMQ6HINYxV1Y0lVcZ3PrPSb9LhUzIcqpxtrZN2wgKsymJlPynvXi/gTxIl7bxLvxKvDZPSvToLtZoRvOcADOP0NNSHOCevQmvFjkkVUIBAyc9QfardrrmoWhVEYSgDP7z0qmWjQhZH3EjqKrSHazsmTuG3AP60XDkU1aSudGPFd5tU/ZIjj0fiqbeIr13DtZouPWTr+lYsU20gMDsx1z3qKe6G91JAx0560XM/qtK9lE15vEWos2Fjt4/T5iagOo6pMwLXCxAjqidPzrIW7BLEsT2yMcZqGW6wrZccHr6ijmtuV7CC2iaN3biYk3NzPPjg7n2j8qpy3Vvbr5dvGFwOT1/Csqe8BfIfk+/Iqo0x3MST045pOZrGk7GvcT58sEZYjJwazdQuFWFpN3ygc1Te5Y7t7cnGK53xFqpEa2sfLv1IHQVnKdiowexX02+WR5ba+Y/Z5XMkUh/5Zsev4Gu68NeG7l/mtmSWKQfK6nPGa47R9MFzGARgjp716D4HnuPDl3skVpLOQ5ZBztPqv+FKld6tGteNov2b17HfeH/CAjiJuXO4gD5eBmtC98NW6wnYX3Hv/AJ610GiajZajbrJaSI2Oqg8j8O1aUkYbBwK7VFPY+aqYuqp+8eS3FpJaXaxyjGWzn1qxHC91ceWq53EfhXeXenW08yb4wxU9TTILG2gdjGijJzxS5Tp+v3irrUy9O06K2Rg6hjt6moL3TrcwptjAJPOO9bc4VVZguc1UmTzHRQcDrVHK68m73OW16zeC2Urnyz29Oa5+eNpF44Fei3SLLhJBuz1+grMvdJtn+ZD5eT2FDhfVHXSxqirSOMS3IjOeSR3pZ0S3htlWRfMlT7pHcdR7cV0ciaXplvv1C6GOyg8se3Fc3cXq30rXMaPDEvCqwxwOneoasaxqubuthmoORbB2G35chK+ffG0xuvEFw38KYUflXrviXVwLVzuOQDuI/pXi14xuLmWVidztmsZyszZpqOp7D8K7ky6PEvHyAjH+fwr1C0Ki2R+jMQwwe3fNeD/C3UFguXtZGxnnnuK9q0+62BQMEqfXg5FOnsbzfMrov6nYhSs1sDnAwytz+dWbLXEQxx3w254Eg6/8CH9abbz72JiMe3OQjHGB6CqN7GjbgQrFzwF9a022MXFVFyzOws54ZV8yBw6/7PIpJWYuWZQD7dq4GKMRymQuVA6hG2/yqX7bNCWZLicAKOr5wx+vai7OWWD10Z3Il9FBPbitGzmbyZWDBWC8BjjJry+XVbx1+a7kHPJHaomuGm+WWeUyEnbuc4qufyI+oy6s7+TUbWAM17dRJIDn5Wzj6YrnPEWtQX0EkWnedJuG3zHXCjj361ziT2iSn7RHIcnnBGc+1UJNQKShwWVFJCR56UOZpHBRTvuWZI4rSF1mZjMU2qi9OK5bULoGN8sAOuPerN7fq5J3EFT371zl/LJfXK2luQGOdzdgPWs3qdNrHuFg42R4JznGcVPeRBoCAQFHXA71l6VMWyAeQeM9jWlIWKugG5jwaaYpK0rnMSsPtL4x8ykdeelPghYiMr+AzS3iNFJGxCgF8N+NaklnPY7VnQ44KnHapjubTnyu3cSzuPJk2u30rUScMuM5zWVdQh8FePU0CVoY1OOgzmtFKxi4qWqNOKTZNjrkE81aicZjOAOcGsgXK743BHXkVddzsZgeh3ValcynBmi0ZW5IGBkd6qXSEaddBR8qsDzVq6YmWF1IyQCKivcrDdxOV/eRnHrmm2YK5xjSqsxUkdT+BqUyKFGTyazblijgnrxxSgM205P51lzM9B07q5YvJBJCAp6nmufNttnmSQZVun+NdNFafIR781De6cWt5J2wAB1OaGmYuajoeI+PYtqoT13EcelcNIueleh/ENAIEbOSZO/euEK9gOlZRdiqm5DYX1xpt0s1u21x1HY+1ev+EvG0d7EE3qs+BlW6/wD1xXj0kZyT2qEM0MiyRMVdeQQcGrcVLbcIVXDfY+nbbV1kGCeG5IzT5LwqNy4wDxnGa8H0XxxeWQEd2pmT+8ODXY6f4z068C4uFR/R/lNZSUo7nXTlCWx3z3RIJDAE1A1yS5Dn5scbv8awItVDKuJFZOuQcig6gm0g4IY5xms+c3suhtrOuCVYo3TBqKWQfccgADJNYb6ioIySFX1qP7Rc3QK20Ej56kDAH40r3M3a5dubhEUlfwOazptQIXDP1PAX1qSTSZyoa6lxkfcTk/ie1NjtY4lbauP507MOZFcPNMPmBRO3qaq39rnypP7h5GecHv8AnWzCnzDIyRUpt1dWDnhuOapRurMyc9bo1fC8SJGu4AKBknGa9Bt7GKeFfK2Adc9q848PyiI+UwyycZHUj1r0DS78pApG4Z4OMH881rCyVjKq3uhZLOaxufPtZHjlzw6ZBq5D4y1q2O11SZQML5ictj3FK9y4OWDPGcc4GT/hVZjBJKzKCgC4VM9c9uO9XtsZ8sKi/eRuaI8ezZ/0jT+ccmN/5A1IPHVgp2ywXMZHrHnH5Vz8kSgPzt44Udfx9KpnbucvtX5SqseeaV33J+qUJfZsdb/wl2mzDKXJA6nejCmHxNYDc/n57DgmuOL+S7JtU7Ru4757VHNcqyL8qHjuMnFVzPuS8DTvpc6efxQDzBFM5HTI2g1k32r6hcjdJLHbR/3E5Y1kG9CSAZ2hQAdveo7rUWkO9W44/h9KOYccNCLukSzeUhWdR5o6F5W5J9qo3uo7UkWMYyABx0H0qhf3hdc5+VABjPWsXUL4RxMzdcZx71Dkb8tlqZfiq6LL5Ktknr7CuQli+bI6emK2rkvLK0j53HpioPIPVhWN7sl6lSwlksrmO4hOGQ5+teyeH9aF5axXET5bADLnkHuK8kaIAZA4q/pF9Nps++HlD95T3FUnYuF1oe1JqfKDgjOBzxU76s+1t4AUjjAxj/GuI03WYbuMMGxx0NWxfHbkPubGBk8VdzVRizqJbuDbjeQNuMk7ifb2qlcXPABYfN88mRjHoKwlnUgg4YnGGHb1xUNxe7QRnvySafMNQVzbM6MCN2C4yB7VDcXCjceSFGR9axHv8szSNk5z1/SqV1qY5AYfLz9anmG4m3PegBRkkhc5Ppisq4vQE5YD3NYd5qgUEggg+tY8l3dalN5NsrSOeODwo9z2FTzX2JasjXvL53G2CN3ZjsXA/i+tdDptiul2583zPt0g/fh1xsOfuj2qbQdNgXRrWGa9iiuoWdm8zIRt38QI79qt63dLLJAscpnMUQR5iCN5yfX64rVRtqc17ysdVYzE4ZMBWx09K6G2uAr7ZQcBs8Vw2j3Z3GNzkj7voa6m0cl1KLjAx71KZdSNnZlvW9NMis0X3XzyPWrdprUN7BFZ6km2QKEDHoant5x5GHyz56elZ+o6ejlpUG9jz0zgUa7ox0mlCfTZl2bS3iXdAwdc5weeMVRms5PIb92etU7e/vrKTaCZYePlPUV0Olaxa3TGKRtsnTa/Bqk7mcva0td0c1NCUU4z6VZ+YqVyema664023n+6AQw4xWfLohVAUJ446VVhLGRktSkPNMFs3VR0IPOasXwaWIuVyR39aalhKkAUltob0qZYpvssigHO3HIqkQ6sd0cFe27NOzN90cVf0+0M5G1OB6itmTTUGwyg7ucjtVuMxRxkAbRj6YqVGzuyqmLvG0SpDp4YMJGCKBk1j+J763EQtLUhscsT0qDXNbJkeO2Ysp4Z+wFc5dzjYSpBJ7juKJy6DpUJStOZ558QnH7hBz+8Y1xRQEnNdN42n83U0jUkhBz9TXPFODmue+ptPcpTJgcAVRYZGe9akqZWqUidhxWsWRa5UK8VCVw3GcVdKdjnjvUTLzWqZNjQ0ppFK7HdB7Ma7DTGlYLuLSL781yujBWcbsZr0DQ41bYNvHrXPJXZ0KXKjoNBt7dxlo03fQVtypnAXgY4qjb2rRKskZOPQVoJKCvvWiSQlK7M273IdpJqgUy3zHitW7QHngk9jVOVAFAHB9KlmiGLtYADikKMSAOQKkgi80nb9KtLEIo8Y596Qm7FMB4ZFkQfOP1Fb+lakGwNwB75NZ6W5cZbgHr6CoZbVgwaIgMO/Y/Wiw+c61JI+kkh2D5x9fQ+3NOjmWNxtfcxyfu4J9Oa5ePUJYDibKMBxnoati83EEyYbgjuPxouUtUb1xOY1AdgMDAyO/071QlkUkAMDGAeD/nrWdPeqCzblBxweoNU5LxQu4spI/SjmGo6GgJlVjuJBJ4Heqz3SiTvtPHXpWXcXqlvvEYHHcms99Q2t94A55NS5WLNee5CNlSTnrVae9DqfmAxWFdajtLfN/8AWrP+3TXDhbVC7dz2H40ucho1b28CxkFunSstg8x3yZ9h/jVu3sCn72dg8nbjgfSiRTknjnik0JalPyssNvSkliG0jJq1HER3qR4uB3J9KLEsy2iwMHp6VItscZGcelXfIzy3b2pwjIB6UWHcgiQxHchKt6itOC6n+UA5PtVeOHGDV20jxITxgDirSJcuwSXZU/PuBA4xVaa9AbKkgYzirTjc3B496sRgAYbnihq4/aNaowJr1ieAWPUYBqFbXULknyreQA924Arr0BGNu0Hv2pQdpYAc0uTuHtpHMQeG2Z8385x/zzj7/jXSafbW9rbCOCBY1H93vSHOSc8YqSOVYXVyquFIO09G9jVxSRDlc6Kxa5GkW39nSW8Tbm80OyBmOeDz7Vn6sLl5kN7IksuzgoVIxk+lNOrw/wDQLss/7p/xqrd3a3BDpBFAAMbIwcH35/zxWjd1uZRTvexcdFh2yKWLDpXR6FqKzfIxVWHGRWLeHewJUjHas0SmCXzIz3wfpWWx3zh7ReZ6hFIQQdu3P41ZV0VnKNuQDoT1rlNL1NZolIble3oa1hcjy1QNgH07UKSOKULPUW5KyHKYz/KqFzCsrIRtZsYOeKuCRC3cr7VBcRhiCOV68UmzaDa0JrO91CwCeRcMyqOUk559jW3b+KJIlxeWzgH+JOR+Vc4lxuGD29KillnJZkYbRjqelUpW2MalCFT4kdkPEVgyHEmM+2DVSTxRZRlkUMx74XtXHtdSqcmQHPtxWTeSyOpG85J55qvaMyWAg2dnf6/Dcf6lCPTccVg31+GP7+VpEb/lmnH5mufilAwrNjB7jvSyyqZGbJHHap5zaOEhTegXs7FMKMKOdoPSsq9ukW3Z3IUqMke1SXM6jcF4XPc9a43xLqgw1vE3X72OwrNzOlqyuznNQmN1eyzHoxyB6elVyexFK745Hf0FQmYck1MdTkeo51+WqUikdqsCZSPm4NQO4buK1SERbc+vSo5Iwz9TVhcY60qp36k1Vwv3HacoWVcjPPSvSvDzKVXoMDgV55brhs9vaux8N3RVQoOMVmpe8apXV0d5HdIqjJ7UvnDk5rPtZFkx0+nrVjO3IJxg9qtsaiiWZge/Paoim9cHGT3oViwG7OB0qzbRB23E8dOlIp6ImhhEUWcH3pUid5PMZQVFW4EUE5H4Zp0hHlkKB3JqrGZGhEh28bQPxFJJGoQbenXmqwYo+AetPMu1SGOc0robiyO9jjeMI4BB9aqLpLvHm3uGTA4WQcfT2q5GpkILDhe5qcMEPGR/KnZMFoc5d2l/ENpVX9Nrc1TmttTjX/jzlx2xg10t622aMkZORWhcspgXOTgdx0qORFubVjzxrbUZn2R2jk+hwKU6LqL8ytDCPUvk/pXSRuTO5zxmm3cpH3T+YpciB1JXsc2uhRK+biV5mHb7q/lV1FSIbIkVVHYVZL5aoGU7iccU+VE3b3DhkwBnn1qCRV3Yz0qwoC4x6VBJ8xOMUNBcZkfwgA+tJjJJ7U7Gfbimn7vFIdxecE54pm4ZodsrUGfmHpR1sIuKwBznH1qzCx8vJ6VnB+duSRmrQkGAEIqibkzvkgdKlibHbOO9VAwzUgYL0yMUBqXmkOc7eKjErE5P5CqgkBPHWnKT1zRcViYyEZyeacZM7fWq68BjSdycc07jSuX4g8jKFjZix2jAzk+n1qW+WKMrC0E8VyoG/e3GfpjitDSb6OPTozGJjParIRGkZZS7dHJHTA9aqas8bm2VZXleCERtLICC5yT0PPeq6Ci3e1jYuue+e3WsyUjk4GT0q453AkEc81RmX5yeT9KzZ3xK6XD2su+JgPbtiuj0/VkuIxyVbA4zXOCDznAA471ekBWJY4hhehIqVEmokzqUvAMrn8T3pTchlyO3SuWjnniBDMWH+1QdSCkBsqc5OaTujJRTOoNwucBQQTgkdaglmZSwbHXGf6Vzw1Reobr2Bpr6qCDhs55OT1pc1i1A0rm52FskbcY6dKz55/MO/gc4FZkupoASW5PUVSk1FmBCKWNTzXNFBJGq9wQev1561Wn1BY4iBgd8k1izXMp64UfmfyqjIzyEgliTVWbJnOKHarqrsrLCMZ71zM+SWLZJJ781rXKkEjI/CqEyYOPWly2OaUnLUzjxULBecjmrc49KquCc59KcWYvcpOo3EioHTByDVphgGoWIxzit0wsmQeYy9DU8Vyy4z0qByMketMG4njFXZMh3TNiO4XAB6VuaLcoknXg+9cjHkkc1qaexU5yawlFJ3NE2j0O2utpBUjnitm3mLqDwe1cVYTMQoOTXQWNw6MB2po0udHGvKg9vStO1VUQY61jwz7ow5BxVywvFaTYxx/WnYm9zRyDntz2pj5KsB1xxT3YEGiUgplTnjGM0xLUz5Qcggc0ibmOMZ96tFCc8UsahSAQPc4pWNeayH42RAH86hLjceAPxq2CHTAPy+uKqzxLknIpkJlG+clVPoeKle43QrwOBxVa4TOBn6Ug+ZcAHjoBQW7MicruJXP071WuGPJzmrLptwcfU1WkU7sZ4NIlorKd3zDp1HOaUkYHJzSH5c+tR+ZxgkeuKCbityME9RUPCnI7U9wSBjB+lRhgRyOfrUlIYzZOaazZ6UrdfaoiPmNIBshz17Ug9+lDglqTGKa3Jd2LznJ6VKGHXBIPvUWDjnNAJGMHii5UUWSemKeH45/GqwckcmkaUgUIGWEb5ztqdcjqOtZkcmHyTj8aspKzcZNNAy0Dkj+VSqm8gdB71DEQgDPzUj3GTxxTJOu0aRG01beC5iiIjmWaN5Am9mHyn39PasXXblS9rEsyzyxQhJZVOQzZPAPfAwM1YtpJf7EtXstPtrxy7iVmhEjJzwpH070/VViks5/Nsra2khtklYxIFMcpbGwkdcjnHarexmnaVyi880D53ErmrVtPDckb+D9KivkAY84/Cs10wco2GrHVHrO0kdC0axfKg+XruxUcK73IIHHtWMl+6kI2dvvWtaXMbS7gwAI71SkmYyi0STRDO4BcGqNxFxnqPYVtyRB4z5fQ+lUjEEcmTkfWqaMLmK1qzsSqgj2qlPbFTyT9K6KaQDIUYA7VmXKZJJzmk0hRm0zPMaon3QOaYXRSx/pUkoJ7YFVyuMk1JTbYnyk+veq0qlWyM81Mx25wPxqvK3fJx9aTkiJRKc3LZxiqNwOeKvSHkiqcoweahsLGdMuDVZxjNaEkeQAOT9Kha3wp3URIaVzHlPOBzUG0k5OMVvWWiXmpy+XY2sszeqjj866zR/hdqV2yNdHykJ4CLuNbJvsJ2R5p5YP1qeGzllBMcTt7BSa+j/D/wjs7VFka3R5RzumO4/l0rov8AhDZbYbYIoSo/hX5ab5iFUpvdny3Fo99gMLOfn/pmav2+nXMJzNBLGp4yykV9FPo+1iksJVuvNVZ9KgbIcDPqe1ZtPdmycGtGeMWA24DYyK1oeDkA5J4Fd1f+HLZsnYpB6YFYd1o7W2RFkr6elO9h8r6DdMl6RvkZqW5heC4Vwpwe9ZkoeNhjOV9q1bK7W4tgjn5l7k81aldWJULamtEzNbBjnp2NUpLlwcLkgcYzWjASbfCrnFZ86uGPGKHoOMbsBfsuBzmnreBgTxjvVJkdjjHSlWHA56+tIpxNGO544Py96R7gMMEgH0IquqhQOwpk3lknOfagXKP8wMOnf1oj25zjJ6Z9KqmaNT8ozSrMWbGDihFWJpD8hx1qhOeM8VbZH6qcg9qrNEXfGRSuSym3IyTiq7HaxJIPFXp7cxjJ5FUJ1GSefbilciw5WwmMdajYneSfyqB5AgI5IFMNwo65+ppNoaTRO7AgVExxmoHuVxxmozcgL8x4+tQ5FWZOWGcmlaQAgMKqmYc8jFQvP701IaiXDKOmacHGKzDPznBNKs8jZCoTmlzD5DReQY4yKYZQcH196q+VdyD5Ijj6Uq2d4WA8ls/Snr2BQT6luMoTkmpvPRAMH8Kz2sL4YJjPsKF0+9ccow/A0uZ9ivZovNeD+JqhkulIGD71EdKumbDBh9at22gyyqASRTXM0Lliupv6F9kjtrVpIZ5J7pJnDpM0agoCQvHUnFZGvywq1pLZwtBbXMIm2FyxLbiCTn3B/Ctey0AWVhayT3V+S8pkRLcgLGy8Z5707UrQ3F0Jh9qlO0Am425+gxgYrSztYwVua5v3VkJQSQR+FY93beXwDzXXSlRuLYJ9KwtSAcnGOnaqcTeNV3OYkXacYzTrYsZPlJGKty24PzHjNQxoQST071lbXQ6PaXVjUt9RaIBJc4HvVrzo5wW3DH1rCkTglunaoVleN8Rt07CtL2MJRXQ25sbflG2qE7gH5sinxagrrtkxuqC6df4SDTMG3fUglKEGqUjAAkUk82045phbPXvUSLjpuROcioGB5B6GrLgY6GoRuZgqg5PQAVm0aaFSVOhzUKW7zSbVVmbsBzXZ6J4Qu7xhJdqYYieh6n/Cu90fw9ZWh2RIiHjLMuc/iapQbInUijy/TPCV/eLkx+THj78g5/Kuw8P/AA5tixkvT50g5Cy/IrfT/wCvXocdn5TBIsM7nbtXvTdQuxas8VqWeT7ruTlR9K2UElqckqrk7IrWOlWempG0cKQSDtwQfoPUVrw3dtHghvnPJwK50yyyS5bLN6mrNv8AK3Iyf0ocuwex5lqzrYb+IKCWGKtRXcUqgIwye+a5RlYjI6dajErq+I2yfbpSM3h77HayWdtPCRKobPc9a5vUdGMZJVTLCecfxD6etNstRkRv3jM2OMZ6Vrw3yTMfLIJ64zVJowtUovQ4q5tNqZRgwHBzwR+fSsy4t1YMCFHPSu9vtLF0HkJCynuo4NcTfqba5eKRAvq1TJHfh66qaLc5i909Z93BXj8659YjaXWG4B447V6DdRxmIA456kVh6pZq8RYDgHhjxUbM6r3QmkXax3CpJ/qz39a1r23XIdACD7cVxrOVXA6r0NdLoepfao1hc5ccCtIyvoZSjZ3RXlj2sc96iCg5zW5dWi9Dkn1rLuITGR3J7UrWGpJlZwMYxSBUC5IzTXbHYUm4NkUgbsQSKmTx1pYwHGBx9KWQBWOBkGmR7i4xxQWtUWYozwM4pZLIkbhwacjHjNWEk4wTijci7M0wMQVdjyetVptLLcEjFbLpubj1pigKSGBOf0o5US0znTpeM8fmKryaScjOQtdc0MboGz1qt5IBGScUuVBGTRyz6TuOcdPaom0cucZI/SupMQUnHzUqW4bLYOfSj2aZbmzlv7Dbb1pn9hy7uBn612C24x1OaPKZTx97vgUvZRF7RnJDRJVIG3J9KuwaPImDsPNdCq4Y85qdWAH+NVyIXM2ZcVnLEu3aCKu29hK7glQPwqyDuYt/DmtOCQBQMjp2qrDehSOl4ALKpx7Vah0+Lbkxg8ZxVwHc/JzViJVHofrVWM3LQzo9JjlJLR4xSnSkUEhcH2rZVgB8ozT87cNtyM8g96djPmZVtYXisIktbiCBgWLhyMt6HmqWorK8qm5kimbb1QjAHpxWrNPDg7rOH8zWddOJHBSFIwBjCk4qm1YiO5nyTEg9T7is+5bjLfjmnXEjITwSKzZrzBO4HmudysdygK4Rl61XKgOADkVWnvNu7apz61TkvyM5Bzmp5yuUvzkEEDrVJhtYntUD3c7KcISvY9KzLi/mDksOKTmCTNKVjhuntVCS6lj4BJHpWfNf3D8Iuas6Po2q63PstkCRD78rfdX/ABp899iXpuNN6C439+nvWjaWt3dndbQSMo744rstG8IafprK0mbu5xnzJBwPoO1dJa2aFsYwvXFUot6syc+yOGsPDV7dyKJdsadz1Ndpo3hm1smDRwhpf+ej8mtcLFCDhTgeg/rRLdKwCAse4VO/41Sig1ZajhjRQJZcPnBCjPFMl1FbSNwcMW+6MYP1qpqGoQWsIdwqMv8ACWySTVCyil1BxPcfLEOVU/xe5/wq0uiIsrXlsbNvdzXKgx5iBG0uOrD0+nvU32cONpAx2pYUULjAAHYVLwVyflUVfKYeaEjt0VAVUDsakJSIYGCfU1GZVX7gpq4BJf5j2FS0Wkx8m50yz7V+tVZpSmRGcDHJ7mnyuSOpI7VWcsTye1SzWK7jROy4Of8A69S2l28UwkGMZ5A71SlU9xgD1qCNzvKrj3qLmrpxkjv7K8jngyWBz0GeRWN4ns47iMyJ98DBFZVnctbuHRuO9b8Ti9gYjndwcdqq90ebOk6E+dbHExBGQxyHoehqvdKuwgbcDj1qfULc22oOjDK59KV9jICAVOM4FQ1c9OL2kupyl3BtJYc881Fab7edJYyQAa2NQQ8gAdfxrKiYRzeXJ91uM+hpJWZc9Vc6yC8S5tlI5+hpksQkw2PpzWHZzm3mwwG0nHJroIHVxlQP6Vqnc5XFxM+6tFCdCCapC3Kkk888V0JiV16Y9+tQtbYXgDNJxDnvoYMsfy/MDn3qMIQRj8a07iEnqenaofJIyMCpsWmQoAOD+RqVVyeSKcYzkZGKccLznPbBpjuMztyMDH0pDhs8D2oaTIye9CHI46UCuxgJj6/d7jFRysDz096lZeRwKiePcKASQIqlixzmnJ9/Axx2qJVIJ3c1MhGc8gigpolYYqJw4xgmpgQc5bBpFwWBOCB3pkMWJBgk8GoSCZcfw1I0gY/L90GgYBxjnFAREwQSO3arMTbQCDyBUOMnHT6GrEOCFHAP0oKb0LkUxHUjJHWpEnHAck5NRrGOhJ564pQibvmGcHFUZuxoRyLkEjNTCVSw3YYZ5GcVmnCg7DipEYKoLNzmmZuJsLGJ03pZ7lHT97isvUkMU4URCI7cld+6rUNwPJgZxIVQtG2BkEMP51V1BQHjiUuTEgQs64J/CqexEb8xl3EBkBwCf5VnXGnsxY7QMe9PXxPbYwSMnrTYdWjupTHGwyenNYXid3vIofYTI+yNMt3zV2Pw0FAaROSK3LF7e2+8ylj/ADq8btHI2MDntTUEZyqy6HI3OklBgJhKyLnRUY8rkk9BXoM0UckqrcSBUPJGcn/61ZyrGkjMBjGdp44ocEKNY5zTvCkDOHuxtUfwg9a6uFY7e3WOBFSNeAFGKhUgvySQeelWhEXAOeByM/8A66FZCcr7iQqeCBnJ6DrU7FkYb12k/wAI701ZfKOEIyeBipluFTk48w9+poDmGGI+UGmyiA8At1qGSWKLkD5enByaW6m8wElwT9ayfNJlA2kgfrQ3Y0SbRoX+nG5njus74h/D/drQsn3ALgcdPak0i4UIEfGG6jPSn3qi0kPlDIbpitYtHK5NvlZYkmEQ5xmq7X2WxVS4dpExk/U1WVHVvmwfbNOUjenTVrs0zcszHGAOlSLO2OvuTVNF+Vd3r0qZXA/wqC2kWXYsQPaoZHHfk0xnDk8kDFNkIPIP44qWxpWIZ3Kk78/SqwkAkLAcnmrcwaY725PcnrTUtCWLPwOox6VDVzVSSVhodm/hxWxody0ciq+VDdOO9ZqkmQKoG0HFb1ha7pUIG9+uTVRRy4lpxaZV8WWAxHOnG/5Tj9KwbIKwkEx/eKcAV6v/AGZBf2P2eZMqRnOea80ZUs9ekhKl1RinI79qtxsznwtbni4djK1O0IBwwPGeRjFcxqEZHHOepxXe6rC72sjYAJGfpXF6gCdwGPxrOSszupz5kQofPhRxjd6+lbujTArtbO4dPeud0yQhJEwOG9K0bdmjbd2zzzTuJq6Ogkk29BweooeYY9MdKrrKHjBJH86gmmxwMVV7mNtSydrnk5z9Ka0Q6L1rPil5Gc4zUy3O1/w4GaLoLD51UD5uMd6pyMX4HT3qdt024twPrQgRAQTSsVexUCDHNOVsNtHFOmxjIwag5UgnoOKQXuTg9Mng9BUe/Bx+lNEgz+HGT1pFO7JNIaRYBAU5HX1qvIg3Eqcn61IOQB0zSFepBzimBXMxRcEYHvTo7oMpUdfaiWNZRzj61Re3kjzjn8aQ00y9GxBBzx9amWTnJrIWV0xu4FPNwM0cyCxsRkKfm9asxsD0BA9axorjsTn3NWUuiCB/WncGma6SKp5I+hqeJ1KksRz0rHM2/GWx9DVpZAoBzmqTIaLvmKDzjFKHbcMEmqhbIOMYqW3JjdWRvmXoc/rVEm1EUuLeKEzGFoyeGUkNnvx3puoMpMSo7P5abS5GC3NTQzGG0jeS8mhMhJCKoPfk1HqEQlTzRdSTMqB/mXGVz2quhjszhNR8IjPyHmsmTQ7ywO6BzkcgCvRLzVQxP2aA7fVjWRcvcTtmTCg+gxXK6S6HoKvfc5W3j1qUHYirHg/PK2ASOw963bEy2yBppi0ueCvAWpVhYOTj3BNWPJ+TPfsKpKxnKfNoCzuSSWO485JqVVz85OR3OaYkZ28+nOKmhhbgqC3uaZk7IQuuOM4HenLdSsRkZxx0qaOEHIfP0ApSMDGMe+KY00xEbJIBA9eKsRsOdgGT1JFVAp3DOc1P8iggjJpWKsguipSMKh8zv6GqE6kN8uMjvWopAQAjAqleEljtHFKWxrTYmn3MgfDV0bAXNuoXhl71ytudsnHWuk06UlAVXtzTpy11McRGzuiIwEICTj2pjLtUkYwO571ogjaVZQe9Zl9JtfHQeldDta5FKTloRPMFzjPXFV5LgeZnJ/Oqty7M2E5PQ4pbdMOpYZFYtvZHeoJK5fg3u2TwvvVtULcKM0kMSsAzHauOnWrny4Cp2HahIxnIjWJkIzgk/pUjRNIuBk/TirEMRYDpgda07ZI4wSR7U+U5p1LGXFY7VXI+Ynp1wK6CIpG6FRgKAABVIPtm56elTJLh8L1J45qloc9STktTsNLIaAN3ryrX2RfFNwB2kzXpujyEgFiRxjHavLvEGJPFF1Ih/wCWvanJ3SsYYJWqSv2LmrSq9ooZdu4du/tXAakC0kgOODjFdVqlwBE2SS2OPauQvJQNxbljzWcj0qStcoWM/lzS7ge1aHnKYtwbr0FZlonmyTfoaJo5FAZTwKhuxe7NeK7bGOi1MZMjOT+Nc+LkpjcCTViO/wAn6UudFcvU1ck4/wAaVW2sC3XtVZLjgH1NRPL/ABDr71SZBfSfk56ZpyyA/LkZrMSfHJHPtTGnO7C9+aq4mjTZx0BzUbMCpAINUvO+Ugg57YqMzfvQo49aVxWsWQ2GxnirYI6dapkooA6tTkkJbg/Wgd2WhwcCiX92hwTupiTLuA5xTJZxI+RRoTqySMcAkfhUjqCuOvrUW8HHr1qcKQu4kU1qJsgazV0BxwKpvp4Mn+zW5bgjIx8o70k0QKcjnPWk4CjUsYRhxggk1MkDAAjn2xV6WIIhGB6GqwkO7A7UJG3NcfEkqHAJHvVuJnRTkcdzRHgsCRV2ONSmPX1qkjNsrq6uvB6U6OQDgHBJ4wKeIkxg9amht0bPr9adiWzRsnAs0+2NbiDJ8sSAsc98Y7VHqVxPEHT90UlRdroONnoPQZp8flGCOK5iZ9mShRsEA9jTdRQv5J2hIvL/AHag5wuT1981XQy66mckbL90k96sLGMZOcdabtyAVOCO1Ojl2j5zx0rBM6ZxGsFVuFGMYppUYO0dT65qZgjLk/jimOuRlcYHQVRBDbp5chDgke9aGFKgqBx6VUEgIIcdufrQk+1lBGAaCNWWmHzcHB704L8+OTioVdvWmvL5ZDNnnoSaV0Ci7k+Bk8EUwpvAIJ46e1RS3HIKf/rpwnymMYNM1SZMATF8xziqs+1h8v0NHmnaR196TIKHdwTSNYqxROYnHHU9a19HuwWKE9eBzWUU3MzYotX8qUFc5BqU2ma1Ic8TqZXPmYbIJ/Wq9zbF4yc9OlT2jrewrjAlX9anRQnyuOenNdUGpI81S5Gc2UIkIwBzjJqeJQAABj3FXr+LLZUDJ7VFFCxYA0uTU7FVUkSRK7BQOlbFjEFUZ5J9R0qGBQFwi8EVNC2CRzVJWMKk7lkooAVfqTSmQIB6E1HvPYc1DKrOuTn8+lDRgvMjubk7+Mj3qWzlMlzHnnByazJXbzcEfd5yasaRODcbh29azKmvdO3jufJt3kz8qgnpXlzSu+pzT5+8xY12Ou3/AJWhTEYGRjpXnYn/ANZtJ6EZApNmeDg0pSI9TvDLOyg7QDjJ6Yrm76VRv29j1q9dy7XwD+dYmoT87U6Dp71mz0NkaWixs0LyY4JwPpWi8GV6DntU+l2fkadEr4B25P1qWRNo9adiLmTJaocjb0rNubKRGJUED2rpHjA57HnNM2o+eOTzUuKNFKxyrSzREgikF9j7w74rpZbSJ04XH171j3enJ823g1HLId0yAXII4xj2prTemc1Snsp4+VzVdppYjl+tJSfUq3Y1VnbHJ4qSKbZzwSeayxeBl6gH3pftHPqKpSM3c1hcYPJp8Vzz1B9qyDMAODSx3BBxmnzEpXNk3AHsT6URyAHPHNZC3OWO7mrMc4JGSBRzIpKxqCXBOKtR3BGMkmseOUD73SpRMB3yKuLM5q50dtcYzz+FTSysVGMEVzsNxjksQPWr0d0j/LuOa0uYctmXv9YSrjC1WuLZ423LyO/vVmBumDke9aEaiX5eCcUWL5rGZBMjAY47VoR4PTINRX2mhD5i5+gqAFox0wfrSSHdPYuNIQ36dKmt2USKWJCqecdcVRU7jzyfrUqNJLIsaj5mIAGe5pks3S9gVDBrn/x2ob+SKQRLHuMaR7QW69T/AI0xI7SMGKS+PmDg7IiQD9aiu4jBtBkEiuu5HHQinqQtyrO5jkxgY6Uw88HgHvT7mMnnnFQo/wA23HI9awR2yV0W4BtQgj6e9O2ls8YqPfhgBmrShXjz/Fimc8tCqkRJB5J75pZFUkDH0qVIygO49ajdQecjigSvcSFw5IJ5qYKGHzZJ+lQeWSdwB/Gp4pMjYxGaY35DFj2vyPlzTmRQMY47etOlPy+rZ6+lN3EgL6UhpsaAAoUkY+lOVVK7scVNHHuzuGAOlSxRhSFPSgpTsUJIdxyvAFR28BeUoO9Xwm2QjPU96uW8IVlYAEnqKLXNPa2QW0L2wV1bI9KvO/nhWxtYdRRMsTR4KMhHcVUgnMMwUsGQ9zWkXynHNc2qLUwjCpleemTTTbhGDA5B7DvRLtkXBOPQ1WMzp8uRkV0LUiMmtC4G2jGO9AO7t19KrQyhzliParSyKBgH8aAbZPEFAHJz70TuCmentVVp8d+fWmSXAPApC1Mu8dsn2NO0p5HkwDtXOMiq+oT4kwWBJrS04LbWocjLAE/WsHuazlaFiDxleR/Z4rPfyfmbmuKluCisikgH171uapE7zPd3DAuwzjOdo9K5S5l3yO2cKDUtm1G0YWRFcMc7mP4e9UtOh+16rCh5UHc2D0AovblQhAB496veHY/JR7huDL0HtUFXu7HWhhgjt0qB23Px0qkkxLHB4qR5zjC8npVD5WSTPtB5qh5j+YCB8vSpTubg8/jT0iGfmxntmkzRWQ4MGj61C4BYBec+tOciPv1phY9c0JisI9uGIwM+tVJ9OWX+GtOJ1KZ6kVISNuOM+1Oxm5NM4+70MlyY/l/rWdNp1xAflbP4V3jAYJ7mqzwoysCuSehqPZoOdnB75kPzL+lBnwvIrsXs1dvuiqtzpUIXG0ZqXB9C1US3Ryyz4GfXtU6XR9cVrnQ1ZRxz3qrcaC6qSjcD1qeWRXPF6ECXXuasJchyQSBWbJpl1D0XdUO6WInzFK/hRdol2exvrcYOOOB61YjucHPB4rnorgk5z1FWI5jnPStFIzsjrba8+6M5HWtazuELcnmuJguuAM/jWnaXbA8NgVop9A9mdssgcY3HGO9QyIkuFJA96yIL47QDg4461etLpWbkVaaM3FoSWJ4cEcjPFJFK6urRsVlVsr359q0yI5SAOnWoJLYJIrpwQchlPINAkTfaA3zy6WGkY5ZkLKCfXFQ3t1JM4EkflBVCrHtICj2zWpPHqtwI5E+0odgDYYgN74rHvVmMx+1NKZFGPn6j2qmSkmzYuEDAHAJ7YrLeHEm5VJPrWrKp5pqRDqfwNcx1t2MhyyyDd+HtV5HyuQ3zEdqjvIcruJNVI5GB+9mncHDmRfzuBEhNR7QJOORSI7EEGljiLZOaZHLbclHynDDjsKZcr8uUOD6ZxUbFgwBOfrUrLwOhzxQZtW1Ft5V2kN16dae0WNsiAkmoXhKsGXrnnitC3HnHHYelNCbtqNQMGBbkVbWPcwGRuqB1bzNo5Aq0V2BQRVpESkRPCHmVc8iteC28pFJx0qOGFQQMA5HUnvV8MLcFZBuPvTUTOU3sVpI3dBtQY5rJvrR1+ZF6dq6S1XeC3Cr9ap3ctvEWCq0jHpxRYUKlnY5pZpkXbIOKlidLhdrMFOepq1Ks8zERwYHvUf2CZRufC9uO1NNouST1K0qPE+NwZR/dFI0zLHkkDHvUzWJPTc2evOKcumB1LO5OO2armY15mY+objhT09KgXUmZ9rFhz1AraW1SMjCKo9ccmmsba2jLy7STzj0qW31K5lskUpUtFgE6tLJMDzntVeXVoQv+sLEnBXHSqd5fNI8gTCp1OKxJn3ZYdPUVNw9nf4mTa5qLuWVW/dk9B6Vz8sq45/KnX05JO3t61h3VyzSYHWs29S1orI0rGB7+7EaH92Dl2HYV0tzGu1RECAuAPpS6HYC302EbNruu5z6k1qfZV2YIyfenYuLUdTJjkAGAMH2NSxHHPXHU1Bcr5Mu3GPShJNqjIJz79KVzRNssKQXJOaeX5/xqJScAjPPamq2JPmPB/SmK6HzqWA6EZqnJLg7W69qvu6rnpiqGox71LxY3egpMSlqTW8vGKuKeMkVz8NyVYK5w1aAuSQMHge9CdyZx1LRkywA6ehqTILYPpVNJAfvYJHqaZ5p8w4IxVE2NHKhSeDjpzVRCZJcn9abJMGUKo4pyFWwOM+1IexOV6YPFNEYPHanqMnDcEd6miAZsdKqxHMVzbq55UGqd1pqOpDxjJ5zW/HEAcjoKsLbo+PSqSM5N2PPL/Q1JJiyCMZrMlsLqJN23K+ten3WnqeMZP86z7iwIByMZqHSQlUkjzYSOGOc8etXba7Kjmt2/0MSMWTG71FYFzZTWjlXXI9faspRcdTqp1VLQ1ra6GRlsVr2930wR1rkEkMeOelXrW7560ozLcbnbw33y84yPSrdnfxrcxO3zBXB25xmuQguc/wAR59K0tOuIhdw+fzCHUv8ATPNbKRm4aanaTeRcyvKNSGGJb51bcPyqrqk0czQpGzSeXGEMjDBf3+lMk1DdeSWupNG1u5zG8eP3Y/hK47e1O1WRYRZRB1crAPmU5B+Y1pc57WaNJ1YtwOKUfMeFB/pVuZQFBGBUYXOQBXPY6G9ClPDuUiswWxWTLcV0RQ5x0FU7iJVXcDn2p2KjUaM0gkHA6d6N5QjGCatQxGRSTUEkPzc5wKYcybBUBw5I57ZqYlcDHQ/lUTWi7vMIy2OpqWJCR146AU7GcmhAdwK54NSW7NESvrT1jbOOhHpTZkEZVl9eRVWMua+hd5ZSWUAgcc1JHN5ke0joetQzy+bEoXAbGCaLeQowxz9aozLIuHD4yQBWksscqqeWbrWOxJlZjnGPWprS4RGwDyTTiS1c1/Id23KxUHoueKke3Ft8zkFvSqM2orHhd/z+xqrcXbygkOTWhKTe5ptqSbiHTntiqVzdrMeBgGs1rrH3gCPaqU13h9ytyOwpN2NYwOijaPy8SHb+NVZ7yKHO1hXPzak4U87j71mXF6ZCQ2SRUuRSp33Nq81XOPkGPUGue1C9aUnDADryetQz3JfCge/BrMvp9qkEjj2rOTubwSjsOnuyV8sfd659ay7q+YnGSagmmLt8oJJqtt+Y+YSAOfxqNWEpIbcO+DIcD+6O5q94S037fftPNzDCQT7t6VmsrTyqkYLFvlA7k16FodkmmafHbxjJHLn1Y00tTFPqaccZVRjgCkfA9fapVuARjvSMc8+taF7mRq8G+LeAMrzxWHGxLAEDFdRdDdEwxnIx1rkbkPBckMO9ZVNNTWm7qxpRyADj0oaToc9TyKpQPuHWpCwIouU1qSmTPA5prE4561CPkB54pwcEH/Gi4milex5G5FIP9arx3RAwwG4Vp8N05rI1CEoxcCokuqKTvoyyt3k49asebuHGOKwY5cZ5qWK65wf50KYOB0MUgI9DU6Ad+1ZVrMCP0q/FIGGf5VojKZfWTb75qeCQDleR2rPV+Rg9Kn4IypwfSrMjYhlUrhuDViHLMACCB71iRuwYZzketX4J1xhuDTQpI19uQQRn+tMlti4/+tUSSElSrbh6e1XfORgM5XjFaGJnyWvHIFZ19YCROVBrec/LtJ3EVWm5jAXHFJgr3OFv9G4LoOhrIaFojh1I57d67yZclgPu1QvbVHU/KDjnpWMoX1R0xm1ozlonKHrwO1XLeQsemPpUsljHj0NO03bZajBNKMxJIrNgdgazUXc35k0aqWixMIp7uGKYnmPazbfYkDANTiF7WXy34ZcHg5BB6EHuKmbi8sXNw8bw8BViZvM5J3IQMHdnvUWqXSC4hiG1WRCGUc7SWJC/gDitdEZKTbsz0C8QBc88ccmohwoooqR9BWPFQzAMhB6UUUELcZbKOBjjNUr35ZBj1oop9EVH4izCA6DdUtsi88UUVaMZ7MjmJSXI71SuJ3DkA4FFFDJiPhmf7OvNWUJKk96KKBSKssrlgCxIPahsrGu0kfSiikMByFJJzmkEroihT3ooqkAskjAZGM0yVQEOKKKtAjGulAJYdc1kSSMTye+KKKyZ0RIDI2G5rPumJY5ooqSepFGdg3ADPrVGd2MvJznNFFN7GT3NnwZbRT3Uk0q7njUbfYnvXWR/LuH86KKUS0Oj4JNTB23DmiiqAbcckD1zXO68iiINjmiipnsXS+IxIJGEuAeK1u1FFYwOqQxyQoxTATyKKKt7kdBwUcU4xI6HcM0UVSM5HM6ggikITOM9KrL94fWiiud7nQti9A7YAz2rUtnZlUk9RRRW0TGZejOFFWoSSDRRWhzM0bRQyYI4JpkihD8oooqiVuWIidgP41aSVmVQcdcUUVoiR5do3+UnpnmofMZpWz60UUPca3IX5cioyoJ5oopPYtGXqcY+Y5PAGPbms7ccgE5+tFFYvc1gSxSzLHJHHPNHHtJ2o5A/KqUJIIHaiik9kNH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discoloration of the nail plate and distal onycholysis (separation of the nail plate from the nail bed) are present in this patient with psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33585=[""].join("\n");
var outline_f32_51_33585=null;
var title_f32_51_33586="Patient information: Electrical burns (The Basics)";
var content_f32_51_33586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83527\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/9/32913\">",
"         Patient information: Acute compartment syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/46/5859\">",
"         Patient information: Acute kidney failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/2/6178\">",
"         Patient information: CPR for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/50/26402\">",
"         Patient information: CPR for children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/59/22450\">",
"         Patient information: Rhabdomyolysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/43/25266\">",
"         Patient information: Skin burns (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/39/34419\">",
"         Patient information: Sudden cardiac arrest (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/55/32625\">",
"         Patient information: Skin burns (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Electrical burns (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/electrical-burns-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H266961724\">",
"      <span class=\"h1\">",
"       What is an electrical burn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An electrical burn is a skin burn that happens when electricity comes in contact with your body.",
"     </p>",
"     <p>",
"      When electricity comes in contact with your body, it can travel through your body. When this happens, the electricity can damage tissues and organs. This damage can be mild or severe &ndash; and it can even cause death. Organs that are commonly damaged include the:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Heart &ndash; People can get abnormal heart rhythms. Their heart can also suddenly stop beating, which is called &ldquo;cardiac arrest.&rdquo;",
"       </li>",
"       <li>",
"        Kidneys &ndash; The kidneys can stop working normally.",
"       </li>",
"       <li>",
"        Bones and muscles &ndash; If the muscles are severely damaged, substances from inside the muscle cells can leak into the blood. This is called &ldquo;rhabdomyolysis.&rdquo; People can also get an abnormal build-up of pressure in a group of muscles, which is called &ldquo;acute compartment syndrome.&rdquo;",
"       </li>",
"       <li>",
"        Nervous system &ndash; People can pass out, have muscle weakness, or eye or ear damage.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H266961739\">",
"      <span class=\"h1\">",
"       What are the symptoms of an electrical burn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on how much electricity came in contact with your body and how long the contact lasted.",
"     </p>",
"     <p>",
"      Electricity can cause different types of skin burns, depending on which skin layers are affected. The terms doctors use to describe different types of burns are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Superficial &ndash; A superficial burn affects only the top layer of the skin. The skin is red, dry, and painful. When you press on the burn, it turns white.",
"       </li>",
"       <li>",
"        Partial-thickness &ndash; A partial-thickness burn affects the top 2 layers of the skin. The skin is red and can leak fluid or form blisters.",
"       </li>",
"       <li>",
"        Full-thickness &ndash; A full-thickness burn affects all the layers of the skin. The burn doesn&rsquo;t usually hurt, because the burned skin can&rsquo;t feel anything. The skin can be white, gray, or black.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms depend on whether or not you have damage to your internal organs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H266961754\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you get an electrical burn, see your doctor or nurse right away. That&rsquo;s because an electrical burn sometimes causes mild skin damage, but severe internal organ and tissue damage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H266961769\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Your doctor or nurse will ask about your injury and do an exam. He or she might order tests to check for organ damage. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        An electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in your heart (",
"        <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H266961807\">",
"      <span class=\"h1\">",
"       How is an electrical burn treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of skin burn you have and how serious it is.",
"     </p>",
"     <p>",
"      Treatments for a mild skin burn can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cooling the burn &ndash; You can put a cool cloth on your burn or soak it in cool water. Do NOT put ice on a burn.",
"       </li>",
"       <li>",
"        Covering the burn with a clean bandage &ndash; Your doctor might also recommend or prescribe a cream or ointment to soothe the skin or prevent an infection.",
"       </li>",
"       <li>",
"        Treating the pain &ndash; To ease your pain, you can raise the burned part of your body above the level of your heart. For example, you can prop your foot or leg up on pillows. You can also take an over-the-counter pain medicine, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;).",
"       </li>",
"       <li>",
"        Getting a tetanus shot, if it has been too many years since your last one",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A severe skin burn is usually treated in the hospital. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Strong prescription pain medicines",
"       </li>",
"       <li>",
"        Special bandages",
"       </li>",
"       <li>",
"        Antibiotic and other types of creams or ointments",
"       </li>",
"       <li>",
"        Surgery to repair the burned area",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will also treat any problems you have from damage to internal organs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H266961822\">",
"      <span class=\"h1\">",
"       Can electrical burns be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent you or a family member from getting an electrical burn, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Put child safety covers on all electrical outlets.",
"       </li>",
"       <li>",
"        Keep electrical cords out of the reach of children.",
"       </li>",
"       <li>",
"        Follow the directions when using electrical appliances.",
"       </li>",
"       <li>",
"        Avoid using electrical appliances in the shower or bath.",
"       </li>",
"       <li>",
"        Turn off the circuit breaker when you are working with electricity.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H266961837\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/43/25266?source=see_link\">",
"       Patient information: Skin burns (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       Patient information: Sudden cardiac arrest (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/2/6178?source=see_link\">",
"       Patient information: CPR for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=see_link\">",
"       Patient information: CPR for children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       Patient information: Acute kidney failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=see_link\">",
"       Patient information: Rhabdomyolysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/9/32913?source=see_link\">",
"       Patient information: Acute compartment syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=see_link\">",
"       Patient information: Skin burns (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?32/51/33586?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83527 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33586=[""].join("\n");
var outline_f32_51_33586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266961724\">",
"      What is an electrical burn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266961739\">",
"      What are the symptoms of an electrical burn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266961754\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266961769\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266961807\">",
"      How is an electrical burn treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266961822\">",
"      Can electrical burns be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266961837\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/9/32913?source=related_link\">",
"      Patient information: Acute compartment syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/2/6178?source=related_link\">",
"      Patient information: CPR for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/50/26402?source=related_link\">",
"      Patient information: CPR for children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=related_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32625?source=related_link\">",
"      Patient information: Skin burns (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/43/25266?source=related_link\">",
"      Patient information: Skin burns (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33587="Auricular blood supply";
var content_f32_51_33587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Auricular blood supply",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior blood supply comes from the superficial temporal artery. The posterior auricle is fed by the posterior auricular artery. There is a supplemental blood supply from branches of the occipital artery. The superficiall temporal artery and posterior auricular artery communicate via the helical arcade; this arcade is the basis for single pedicle reimplantation of a total avulsion of the auricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33587=[""].join("\n");
var outline_f32_51_33587=null;
var title_f32_51_33588="Omeprazole, clarithromycin, and amoxicillin: Patient drug information";
var content_f32_51_33588=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Omeprazole, clarithromycin, and amoxicillin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/52/33609?source=see_link\">",
"     see \"Omeprazole, clarithromycin, and amoxicillin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14597145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omeclamox-Pak&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14455676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14455678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14455677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3795864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to omeprazole, clarithromycin, and amoxicillin, any penicillin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14455682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14455683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hip, spine, or wrist fractures may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14455684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2769659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14455680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take right before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14455681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14455685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14455686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85638 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33588=[""].join("\n");
var outline_f32_51_33588=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14597145\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455676\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455678\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455677\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455682\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455683\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455684\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455680\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455681\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455685\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455686\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/52/33609?source=related_link\">",
"      Omeprazole, clarithromycin, and amoxicillin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33589="Azithromycin (systemic): Patient drug information";
var content_f32_51_33589=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azithromycin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=see_link\">",
"     see \"Azithromycin (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/3/6200?source=see_link\">",
"     see \"Azithromycin (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7983183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zithromax&reg;;",
"     </li>",
"     <li>",
"      Zithromax&reg; TRI-PAK&trade;;",
"     </li>",
"     <li>",
"      Zithromax&reg; Z-PAK&reg;;",
"     </li>",
"     <li>",
"      Zmax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7983184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Azithromycin&reg;;",
"     </li>",
"     <li>",
"      Ava-Azithromycin;",
"     </li>",
"     <li>",
"      Azithromycin for Injection;",
"     </li>",
"     <li>",
"      CO Azithromycin;",
"     </li>",
"     <li>",
"      Dom-Azithromycin;",
"     </li>",
"     <li>",
"      GD-Azithromycin;",
"     </li>",
"     <li>",
"      Mylan-Azithromycin;",
"     </li>",
"     <li>",
"      Novo-Azithromycin;",
"     </li>",
"     <li>",
"      PHL-Azithromycin;",
"     </li>",
"     <li>",
"      PMS-Azithromycin;",
"     </li>",
"     <li>",
"      PRO-Azithromycin;",
"     </li>",
"     <li>",
"      ratio-Azithromycin;",
"     </li>",
"     <li>",
"      Riva-Azithromycin;",
"     </li>",
"     <li>",
"      Sandoz-Azithromycin;",
"     </li>",
"     <li>",
"      Zithromax&reg;;",
"     </li>",
"     <li>",
"      Zithromax&reg; For Intravenous Injection;",
"     </li>",
"     <li>",
"      Zmax SR&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azithromycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3314819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have turned yellow or had liver side effects with this drug before.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4186197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699131",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Zmax&reg;: If you throw up within 1 hour of taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zithromax&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Empty single dose liquid (suspension) packet in",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        4",
"       </sub>",
"       cup of water. Mix well and drink. Rinse cup with more water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zmax&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take liquid (suspension) on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zithromax&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699492",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) or tablets at room temperature. Throw away any part of suspension not used after 10 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Zmax&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699644",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use within 12 hours of making.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10968 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-42AE1A7C96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33589=[""].join("\n");
var outline_f32_51_33589=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983183\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983184\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030861\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030863\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030862\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030867\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030868\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030870\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030865\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030866\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030871\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030872\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/11/21683?source=related_link\">",
"      Azithromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/42/13988?source=related_link\">",
"      Azithromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/2/10275?source=related_link\">",
"      Azithromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17817?source=related_link\">",
"      Azithromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/3/6200?source=related_link\">",
"      Azithromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33590="Gene therapy for primary immunodeficiency";
var content_f32_51_33590=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gene therapy for primary immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33590/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33590/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33590/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33590/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33590/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33590/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/51/33590/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy is one of two technologies (the other is hematopoietic cell transplantation, HCT) with the potential to cure genetic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The goal of gene therapy is to correct the deficiency by introducing a functional copy of the patient's defective gene into the appropriate cells.",
"   </p>",
"   <p>",
"    A potential alternative or adjunctive therapy to gene therapy or HCT is mutation-targeted drug treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5\">",
"     5",
"    </a>",
"    ]. These pharmacogenetic agents correct genetic mutations at the nuclear level.",
"   </p>",
"   <p>",
"    Hematopoietic cell transplantation and medical therapy of immune deficiencies are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy has the potential to cure genetically based diseases. The gene copy must be introduced into a sufficient number of cells and also be adequately expressed for its product to correct the deficiency.",
"   </p>",
"   <p>",
"    Current strategies attempt to use genetically-engineered viruses to carry the DNA of interest into host cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Viral genes required for propagation are replaced with a working copy of the human gene of interest. Viral DNA signals cause the DNA to be inserted into the host genome when retroviral or lentiviral vectors are used. Success is more likely with expression of genes that confer a development or survival advantage over untransduced cells.",
"   </p>",
"   <p>",
"    Gene therapy is complicated by technical difficulties and risks of side effects from genomic manipulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     X-linked SCID",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked severe combined immune deficiency (SCID) is caused by mutations in the gene encoding the cytokine receptor subunit gamma-c (the \"common\" gamma chain) (",
"    <a class=\"graphic graphic_figure graphicRef57323 \" href=\"UTD.htm?25/37/26197\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/8\">",
"     8",
"    </a>",
"    ]. This receptor subunit is shared by at least six different cytokine receptor complexes: the receptors for interleukins-2, -4, -7, -9, -15, and 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/9\">",
"     9",
"    </a>",
"    ]. Gene therapy is successful in reconstituting immune function in infants with X-linked SCID, but appears to be less effective in older children and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6,10\">",
"     6,10",
"    </a>",
"    ]. Initial trials enrolled patients who lacked an HLA-identical family donor for HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1316?source=see_link\">",
"     \"X-linked severe combined immunodeficiency (SCID)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient bone marrow is harvested and enriched for hematopoietic stem cells using anti-CD34 antibodies. CD34+ stem cells are then cultured and stimulated with cytokines. The activated CD34+ stem cells are transduced in vitro with a retroviral vector carrying a gamma-c gene. The retroviral RNA is reverse transcribed to DNA and integrated into the host genome. Transduced cells are then infused into the patient without any prior conditioning regimen. New immune cells expressing the transgene are usually first detected at around four to six weeks, but it generally takes three to six months for functional immune reconstitution.",
"   </p>",
"   <p>",
"    Twenty infants with X-linked SCID have been treated with gene therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6,7,11-16\">",
"     6,7,11-16",
"    </a>",
"    ]. Ninety-five percent exhibited engraftment of fully functional mature T cells, and most had sustained reconstitution. Many also had sufficient humoral responses to eliminate the need for gamma globulin replacement, even though the fraction of transduced B cells was small and became undetectable six to ten years after therapy. Normal transduced natural killer cells were also seen, albeit in low numbers. Previously established infections were cleared, and no new serious infections have occurred in any of the patients who achieved reconstitution of T cell function.",
"   </p>",
"   <p>",
"    Gene therapy was not successful in reconstituting immune function in four out of five older patients (age 10 to 20 years), several of whom had failed allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. However, increased growth rates and subjective improvements in well-being were reported in two of the five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious adverse events may occur with successful gene therapy. Five children with X-linked SCID who received therapy with the gamma-c gene developed a T-cell acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6,16-20\">",
"     6,16-20",
"    </a>",
"    ]. Retroviral vectors preferentially integrate into gene-rich regions, especially near transcription start sites, and sometimes into common fragile sites (eg, LMO-2). This preferential integration probably contributed to the high rate of leukemia seen in these trials. In several patients, the provirus was shown to have integrated within the LMO-2 oncogene locus, resulting in aberrant transcript expression [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Activation of this oncogene locus is associated with the development of T-cell acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/23\">",
"     23",
"    </a>",
"    ]. In mouse models, the therapeutic gene itself was subsequently shown to have oncogenic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link&amp;anchor=H14#H14\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\", section on 'T cell acute lymphoblastic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Federal Drug Administration (FDA) first placed a clinical hold on \"all active gene therapy trials using retroviral vectors to insert genes into blood stem cells\" because of these cases of leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/18\">",
"     18",
"    </a>",
"    ]. Subsequently, such therapy was allowed to continue on a case-by-case basis if no other treatment was available. Four of the five children with iatrogenic leukemia were successfully treated with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. In addition, polyclonal populations of transduced T cells were restored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adenosine deaminase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of adenosine deaminase (ADA) deficiency was the first application of gene therapy in immune deficiency. Gene therapy for ADA deficiency appears to be most effective when patients are treated with myelosuppressive chemotherapy and withdrawn from PEG-ADA therapy prior to receiving gene therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6\">",
"     6",
"    </a>",
"    ]. Case series of patients with ADA deficiency who have received gene therapy show excellent outcomes at four-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/25\">",
"     25",
"    </a>",
"    ]. A detailed discussion on the use of gene therapy in this disorder is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link&amp;anchor=H11#H11\">",
"     \"Adenosine deaminase deficiency: Treatment\", section on 'Gene therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic granulomatous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical response to gene therapy for chronic granulomatous disease (CGD) has been complicated by insertional activation of cancer-associated genes. A detailed discussion of the use of gene therapy in this disorder is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link&amp;anchor=H12#H12\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\", section on 'Gene therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of gene therapy in other primary immunodeficiency disorders is an active area of research using mouse models, with a few clinical trials now underway [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Gene therapy is currently being investigated for leukocyte adhesion deficiency (LAD); SCID with deficiencies in JAK3, RAG2, or Artemis; and Wiskott-Aldrich syndrome (WAS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Limitations of gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several important obstacles to overcome before gene therapy finds more widespread clinical utility [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One concern is the association of lymphoproliferative disease with gene therapy. Several approaches to reduce the risk of insertional oncogenesis are under development:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inactivation of gammaretroviral long terminal repeats (LTRs) that have intrinsic promoter-enhancing activity [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of alternative viral vectors, such as lentiviruses or foamy viruses, that are less likely to integrate near regulatory elements of genes [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/6,27,28\">",
"       6,27,28",
"      </a>",
"      ]. However, lentiviruses have a tendency to insert into transcribed genes, leading to the production of aberrantly spliced transcripts and deregulated (increased or decreased) gene expression [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. The vector sequence can be recoded to remove these cryptic splice signals, which may improve the safety of lentiviral vectors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other important technical obstacles include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolation of the appropriate cell population for transduction. Transduction of pluripotent hematopoietic stem cells is ideal for disorders involving genes expressed in multiple leukocyte lineages [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/31\">",
"       31",
"      </a>",
"      ]. It is only now becoming possible to isolate significant quantities of these cells from humans.",
"     </li>",
"     <li>",
"      The efficiency with which genes are transduced into target cells. Generally, 0.1 percent or fewer blood leukocytes carry retroviral vector markers over the long term in clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/12\">",
"       12",
"      </a>",
"      ]. This is particularly an issue if transduced cells do not have a significant survival advantage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      differentiation advantage in comparison to untransduced cells.",
"     </li>",
"     <li>",
"      Correction of defects in which proper regulation of gene expression is required necessitates vectors containing appropriate control sequences, or site specific gene integration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MUTATION-TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations of gene therapy, which are related to the requirements of gene addition, have spurred research into approaches that involve gene repair [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5\">",
"     5",
"    </a>",
"    ]. Most primary immunodeficiencies are caused by a multiple of different types of mutations (eg, nonsense, splice site, frameshift, and",
"    <span class=\"nowrap\">",
"     missense/in-frame)",
"    </span>",
"    that vary in frequency depending on the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of drugs have been evaluated for their potential in mutation-targeted therapy. Classes of drugs include translational read-through compounds, antisense oligonucleotides, engineered zinc-finger nuclease fusion proteins, and chimeric",
"    <span class=\"nowrap\">",
"     RNA/DNA",
"    </span>",
"    oligonucleotides (chimeraplasts). Some of these drugs, such as engineered zinc-finger nuclease fusion proteins and homing endonucleases, mediate true gene correction, whereas other drugs, such as the read-through compounds, allow for production of a normal protein without correcting the underlying genomic DNA mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonsense mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonsense mutation is a single nucleotide substitution that creates a premature termination (stop) codon (PTC), resulting in a truncated protein that is often unstable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonfunctional (",
"    <a class=\"graphic graphic_figure graphicRef78399 \" href=\"UTD.htm?36/37/37458\">",
"     figure 2",
"    </a>",
"    ). The first compounds identified that could &ldquo;read-through&rdquo; PTCs were aminoglycosides [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 14 percent of patients with ataxia-telangiectasia (AT) have nonsense mutations in the ataxia-telangiectasia mutated (ATM) gene. As little as 5 to 20 percent of normal levels of ATM is sufficient in some patients with AT to slow neurologic progression. In vitro and ex vivo studies demonstrated that several different aminoglycosides were able to induce PTC read-through, leading to production of functional full-length ATM protein [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/33\">",
"     33",
"    </a>",
"    ]. The read-through activity of the drugs appeared to be specific to disease-causing premature stop codons, since true termination codons were not affected.",
"   </p>",
"   <p>",
"    There are two major limitations to the use of aminoglycosides as read-through compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5\">",
"     5",
"    </a>",
"    ]. The first is that high levels, often cytotoxic, are required. The second is that they often do not efficiently cross the blood-brain barrier.",
"   </p>",
"   <p>",
"    Research is now focusing on designing aminoglycosides with increased activity and reduced toxicity and finding alternatives to aminoglycosides to overcome these obstacles. One such alternative is PTC124, a compound that was able to selectively and specifically read-through nonsense mutations of Duchenne muscular dystrophy in ex vivo human and murine models [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26666?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of Duchenne and Becker muscular dystrophy\", section on 'Ataluren'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, the underlying single nucleotide substitution can be corrected using zinc-finger proteins (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Frameshift mutations'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Splice site mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A splice site mutation is a mutation (usually a single nucleotide substitution, but may also be an insertion or deletion of a sequence of nucleotides) that disrupts the specific site at which splicing of an intron occurs in pre-mRNA (",
"    <a class=\"graphic graphic_figure graphicRef60789 \" href=\"UTD.htm?9/43/9904\">",
"     figure 3",
"    </a>",
"    ). The result is production of an aberrant protein. Antisense oligonucleotides are able to correct splicing mutations with specific chemical properties by redirect splicing from the mutated splice site to a nearby alternative splice site [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. Antisense morpholino oligonucleotides were successfully used to correct splicing mutations in the ATM gene ex vivo. Efforts are ongoing to improve delivery into cell nuclei, and developing compounds that can cross the blood-brain barrier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Frameshift mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frameshift occurs when a sequence of nucleotides not divisible by three is inserted or deleted. These mutations shift the reading frame for all downstream codons (",
"    <a class=\"graphic graphic_figure graphicRef78767 \" href=\"UTD.htm?12/14/12515\">",
"     figure 4",
"    </a>",
"    ). Zinc-finger proteins engineered to recognize two DNA regions flanking a mutation can be fused to a nuclease that induces a double-strand break [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. This DNA cleavage enhances ex vivo homologous recombination between the targeted chromosome and an extrachromosomal DNA donor. In an ex vivo model of X-linked SCID, this approach yielded genetic modification in approximately 18 percent of human cells, a level sufficient for potential therapeutic effect.",
"   </p>",
"   <p>",
"    Another approach under exploration is using antisense oligonucleotides to generate an in-frame deletion to skip a mutation containing exon [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5,38\">",
"     5,38",
"    </a>",
"    ]. The hope is that the resultant shortened protein product will still have at least partial function. Clinical improvement is seen in patients with Duchenne muscular dystrophy treated with these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Missense and in-frame mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Missense mutations come in two forms: nonsynonymous, in which the point mutation alters a codon such that a different amino acid is translated, and synonymous or silent, in which the point mutation does not alter the final protein product (",
"    <a class=\"graphic graphic_figure graphicRef55798 \" href=\"UTD.htm?4/50/4899\">",
"     figure 5",
"    </a>",
"    ). Many of the nonsynonymous missense mutations are probably nondeleterious DNA variants or single-nucleotide polymorphisms (SNPs). An in-frame mutation occurs when a sequence of nucleotides divisible by three is inserted or deleted. This mutation does not shift the triplet reading frame, but can result in an abnormal protein product.",
"   </p>",
"   <p>",
"    Chimeric",
"    <span class=\"nowrap\">",
"     RNA/DNA",
"    </span>",
"    oligonucleotides (chimeraplasts) are potential pharmacogenetic agents to treat missense mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33590/abstract/5\">",
"     5",
"    </a>",
"    ]. The chimeraplast is identical to the mutated region, with one exception: the mutated base is replaced with the correct base. The chimeraplast anneals to the mutated region except at the base pair mismatch. This leads to the activation of the mismatch repair system that corrects the missense mutation. Clinical trials of this method have not yet begun.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gene therapy for primary immunodeficiency is still in its infancy. The most promising results are with adenosine deaminase deficiency and X-linked severe combined immunodeficiency, although one-quarter of the latter group developed leukemic proliferation. While there have been some clinical successes, several obstacles remain. Advances in gene transduction protocols and improved viral vectors are needed to increase efficacy and decrease side effects such as lymphoproliferative disorders. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Gene therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=see_link&amp;anchor=H11#H11\">",
"       \"Adenosine deaminase deficiency: Treatment\", section on 'Gene therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutation-targeted therapies are based upon novel compounds that can repair gene mutations. These include read-through compounds for nonsense mutations, antisense oligonucleotides for splice site and frameshift mutations, zinc-finger nuclease fusion proteins for frameshift mutations, and chimeraplasts for missense mutations. These pharmacogenetic agents are in the early stages of development for primary immunodeficiency disorders. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mutation-targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/1\">",
"      Kohn DB. Update on gene therapy for immunodeficiencies. Clin Immunol 2010; 135:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/2\">",
"      Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Cavazanna-Calvo M. Gene therapy for primary immunodeficiencies. Immunol Allergy Clin North Am 2010; 30:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/3\">",
"      Pessach IM, Notarangelo LD. Gene therapy for primary immunodeficiencies: looking ahead, toward gene correction. J Allergy Clin Immunol 2011; 127:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/4\">",
"      Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy for primary adaptive immune deficiencies. J Allergy Clin Immunol 2011; 127:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/5\">",
"      Hu H, Gatti RA. New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals. Curr Opin Allergy Clin Immunol 2008; 8:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/6\">",
"      Sokolic R, Kesserwan C, Candotti F. Recent advances in gene therapy for severe congenital immunodeficiency diseases. Curr Opin Hematol 2008; 15:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/7\">",
"      Qasim W, Gaspar HB, Thrasher AJ. Update on clinical gene therapy in childhood. Arch Dis Child 2007; 92:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/8\">",
"      Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/9\">",
"      Notarangelo LD, Giliani S, Mella P, et al. Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model. Immunobiology 2000; 202:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/10\">",
"      Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood 2005; 105:4255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/11\">",
"      Chinen J, Puck JM. Perspectives of gene therapy for primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2004; 4:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/12\">",
"      Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/13\">",
"      Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 2002; 76:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/14\">",
"      Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/15\">",
"      Chinen J, Davis J, De Ravin SS, et al. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 2007; 110:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/16\">",
"      Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/17\">",
"      Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118:3132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/18\">",
"      \"The Pink Sheet\". Gene therapy trial clinical hold will be topic of FDA, NIH meetings. January 20, 2003; 65:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/19\">",
"      Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3:477.",
"     </a>",
"    </li>",
"    <li>",
"     The American Society of Gene Therapy is a non-profit medical, scientific, and professional organization devoted to the research and development of therapies that involve the introduction of genetic material and/or cells into the body to treat or prevent disease. Resources include news releases regarding reported side effects in gene therapy trials. www.asgt.org/ (Accessed on January 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/21\">",
"      Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/22\">",
"      Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/23\">",
"      McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/24\">",
"      Woods NB, Bottero V, Schmidt M, et al. Gene therapy: therapeutic gene causing lymphoma. Nature 2006; 440:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/25\">",
"      Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/26\">",
"      Rans TS, England R. The evolution of gene therapy in X-linked severe combined immunodeficiency. Ann Allergy Asthma Immunol 2009; 102:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/27\">",
"      Vassilopoulos G, Trobridge G, Josephson NC, Russell DW. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 2001; 98:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/28\">",
"      Throm RE, Ouma AA, Zhou S, et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009; 113:5104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/29\">",
"      Moiani A, Paleari Y, Sartori D, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 2012; 122:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/30\">",
"      Cesana D, Sgualdino J, Rudilosso L, et al. Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 2012; 122:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/31\">",
"      Thrasher AJ, Goldman J, de Alwis M, et al. Gene therapy for primary immunodeficiency. Biochem Soc Trans 1997; 25:537.",
"     </a>",
"    </li>",
"    <li>",
"     ID bases are locus-specific databases for immunodeficiency-causing mutations. The aim of the website is to establish database for every immunodeficiency or provide links to those maintained elsewhere. file://bioinf.uta.fi/base_root/ (Accessed on January 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/33\">",
"      Lai CH, Chun HH, Nahas SA, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 2004; 101:15676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/34\">",
"      Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/35\">",
"      Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med 2010; 363:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/36\">",
"      Du L, Pollard JM, Gatti RA. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci U S A 2007; 104:6007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/37\">",
"      Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33590/abstract/38\">",
"      van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357:2677.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3938 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-0E2FFF80EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33590=[""].join("\n");
var outline_f32_51_33590=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      X-linked SCID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adenosine deaminase deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic granulomatous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Limitations of gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MUTATION-TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonsense mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Splice site mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Frameshift mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Missense and in-frame mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3938\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3938|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/37/26197\" title=\"figure 1\">",
"      Gene therapy SCID X",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/37/37458\" title=\"figure 2\">",
"      Nonsense mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/43/9904\" title=\"figure 3\">",
"      Types of splicing mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/14/12515\" title=\"figure 4\">",
"      Frameshift mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/50/4899\" title=\"figure 5\">",
"      Missense mutation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/43/27320?source=related_link\">",
"      Adenosine deaminase deficiency: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26666?source=related_link\">",
"      Treatment of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1316?source=related_link\">",
"      X-linked severe combined immunodeficiency (SCID)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33591="Leptin and end-stage renal disease";
var content_f32_51_33591=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Leptin and end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33591/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33591/contributors\">",
"     Lynda Szczech, MD, MSCE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33591/contributors\">",
"     Jula K Inrig, MD, MHSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33591/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33591/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33591/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33591/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/51/33591/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin is the 16,000 Dalton protein product of the obesity gene (ob), which is mainly produced by adipocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/1\">",
"     1",
"    </a>",
"    ]. In animal models, it is a potent anorectic and regulates energy expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] and may be similarly involved in body weight maintenance in humans.",
"   </p>",
"   <p>",
"    Leptin is released into the bloodstream, where it binds to leptin-binding proteins and is transported into the cerebrospinal fluid by receptors in the choroid plexus via a saturable transport mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/5\">",
"     5",
"    </a>",
"    ]. It exerts its major effect on the hypothalamus, where a",
"    <span class=\"nowrap\">",
"     Jak/STAT",
"    </span>",
"    signal cascade is activated. This decreases production of neuropeptide Y (NPY), an extremely potent appetite stimulant, thereby resulting in suppressed appetite, increased energy expenditure, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, leptin suppresses alpha-melanocyte-stimulating hormone, a compound that also blocks feelings of hunger.",
"   </p>",
"   <p>",
"    Investigators have therefore postulated that leptin may be related to the anorexia and protein energy wasting frequently observed in patients with end-stage renal disease. A review of leptin in patients with chronic kidney disease is presented here. Detailed discussions relating to the physiology of leptin and the pathogenesis of obesity are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link\">",
"      \"Pathogenesis of obesity\"",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ob/ob",
"    mice have genetic traits that result in marked obesity, hyperphagia, glucose intolerance, insulin resistance, low energy expenditure, and sterility. When these mice are exposed to circulating factors from normal mice, they reduce food intake and experience weight loss. Via a positional cloning approach, this factor was isolated and subsequently named leptin from the Greek word leptos, meaning 'thin' [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/1\">",
"     1",
"    </a>",
"    ]. When recombinant leptin is exogenously administered to",
"    <span class=\"nowrap\">",
"     ob/ob",
"    </span>",
"    mice, food intake is reduced and physical activity is enhanced, leading to weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A distinct obese strain of mice that is phenotypically identical to the",
"    <span class=\"nowrap\">",
"     ob/ob",
"    </span>",
"    mouse is the",
"    <span class=\"nowrap\">",
"     db/db",
"    </span>",
"    mouse. These mice have a mutation in the leptin receptor, with hyperleptinemia due to receptor resistance.",
"   </p>",
"   <p>",
"    The leptin receptor, which has several isoforms, is expressed mainly in the brain (especially in the hypothalamus), but it is also found elsewhere, including the pancreas, kidney, liver, and the reproductive and hematopoietic organs [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/7\">",
"     7",
"    </a>",
"    ]. The kidney expresses mRNA for the full-length receptor, suggesting that leptin may exert functional effects on this organ. The presence of receptors in several peripheral organs also implies that, in humans, leptin is involved in pathways other than energy metabolism alone.",
"   </p>",
"   <p>",
"    Leptin levels are proportionate to the adipose tissue mass and are elevated in obese humans [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/8\">",
"     8",
"    </a>",
"    ]. This has led to the hypothesis that obese humans are resistant to leptin, possibly due to a diminished ability to transport leptin across the blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link\">",
"     \"Pathogenesis of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insight into its effects in humans is derived from observations in patients with congenital leptin deficiency, a rare disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Two affected children had hyperphagia, excessive weight gain in early life, and severe obesity; however, unlike the",
"    <span class=\"nowrap\">",
"     ob/ob",
"    </span>",
"    mice, they did not have impairment of energy expenditure, oxygen consumption, hypothermia, or glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/11\">",
"     11",
"    </a>",
"    ]. One child was treated with recombinant methionyl leptin subcutaneously for 12 months with a significant decrease in fat mass and total weight without change in lean mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LEPTIN REMOVAL BY THE KIDNEY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidneys play a significant role in the plasma removal of leptin. Given its size (16,000 Daltons), leptin is freely filtered by the glomerulus. However, while leptin is freely filtered, little or no leptin cleared by the kidneys appears in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/12\">",
"     12",
"    </a>",
"    ]. Renal processing of leptin appears to occur through renal tubular uptake and cellular degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one investigation of 16 healthy subjects who underwent renal artery and vein sampling for leptin levels, there was a 13 percent renal fractional extraction of leptin with negligible urinary excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/12\">",
"       12",
"      </a>",
"      ]. It was calculated that renal leptin uptake accounted for approximately 80 percent of all leptin removed from plasma.",
"     </li>",
"     <li>",
"      In another study, leptin levels in the aortic and renal vein were measured in subjects with varying degrees of renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/13\">",
"       13",
"      </a>",
"      ]. A similar 12 percent decrease of leptin levels across the renal vasculature bed was noted in adults with intact renal function. However, in patients with moderate renal insufficiency (serum creatinine concentration of 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [221",
"      <span class=\"nowrap\">",
"       &micro;mol/L]),",
"      </span>",
"      no renal clearance of leptin was observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in the setting of normal renal function, the kidneys appear to play a significant role in leptin metabolism; however, the exact mechanism and location of degradation remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considering not all patients with advanced kidney failure exhibit elevated serum leptin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/13\">",
"     13",
"    </a>",
"    ], there is likely another, currently unknown, mechanism for clearance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolism of leptin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/15\">",
"     15",
"    </a>",
"    ]. Investigators have hypothesized that lung, liver, or muscle tissues could play a role in leptin metabolism, as these tissues also express leptin receptor messenger RNA. However, in the presence of normal renal function, no plasma removal of leptin via lung, liver, or muscle tissue has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/16\">",
"     16",
"    </a>",
"    ]. This study supports prior research in rats, which revealed that the leptin receptor does not play a significant role in leptin degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HYPERLEPTINEMIA IN CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not all patients with chronic kidney disease (CKD) have elevated serum leptin levels as reported in some studies, a significant elevation is noted when such levels are adequately corrected for body fat mass and age [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The leptin that accumulates in patients with CKD is the bioactive, free form and not the protein-bound form, which is most prevalent in lean healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/13,19-22\">",
"     13,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact cause of elevated serum leptin in CKD patients is not well understood; there are data suggesting that several factors may be involved, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loss of functioning renal mass",
"     </li>",
"     <li>",
"      Dialyzer membranes",
"     </li>",
"     <li>",
"      Dialysis modality",
"     </li>",
"     <li>",
"      Low erythropoietin levels",
"     </li>",
"     <li>",
"      Chronic inflammation",
"     </li>",
"     <li>",
"      Hyperinsulinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Loss of renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are some conflicting data [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/23-27\">",
"     23-27",
"    </a>",
"    ], multiple studies reveal that a decrease in glomerular filtration rate leads to the accumulation of leptin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/13,20,28-33\">",
"     13,20,28-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemodialysis membranes and dialysis modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients maintained by either hemodialysis or peritoneal dialysis have increased levels of leptin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. With hemodialysis, the type of dialysis membrane utilized appears to affect the clearance of leptin, with low flux membranes unable to eliminate the molecule; by comparison, high flux membranes lower free leptin levels by approximately 30 percent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 36 chronic hemodialysis patients, no significant clearance of leptin was noted with low-flux, cuprophane-based dialysis membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/13\">",
"       13",
"      </a>",
"      ]. These findings, which have been observed by others [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/17,36,37\">",
"       17,36,37",
"      </a>",
"      ], are expected given leptin's weight of 16,000 daltons; a molecule this size is not usually removed by these membranes.",
"     </li>",
"     <li>",
"      Several studies utilizing high flux membranes with the capability of removing solutes up to 50,000 daltons found that free serum leptin is reduced by 25 to 30 percent or more after dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/21,36-38\">",
"       21,36-38",
"      </a>",
"      ]. However, protein-bound leptin, which has a molecular weight of 200,000 daltons, is not cleared by conventional hemodialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated leptin levels are also observed in those undergoing maintenance peritoneal dialysis. Peritoneal dialysis does not significantly clear leptin, with measured peritoneal clearances of only 0.7 to 1.7",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or 2 liters per day [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/27,39\">",
"     27,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local visceral fat production of leptin may also contribute to increased levels in peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/26,35,39\">",
"     26,35,39",
"    </a>",
"    ]. This is supported by the observation that leptin secretion by cultured adipocytes is enhanced by high glucose medium (such as peritoneal dialysate) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Low erythropoietin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low erythropoietin levels found in patients with end-stage renal disease and withholding erythropoietin administration in such patients are associated with increased serum leptin levels. In one study, levels of leptin and NPY were measured sequentially among hemodialysis patients receiving or not receiving erythropoietin, as well as in healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/42\">",
"     42",
"    </a>",
"    ]. Among those administered erythropoietin, leptin levels significantly declined after 3, 6, and 12 months of therapy, when compared to dialysis patients not receiving the agent.",
"   </p>",
"   <p>",
"    Elevated leptin levels also influence sensitivity to erythropoietin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/43\">",
"     43",
"    </a>",
"    ]. This may be due to a direct or indirect (via adipokines) stimulation of erythropoiesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptin gene expression is stimulated by pyrogenic cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/44\">",
"     44",
"    </a>",
"    ], such as TNF-alpha and IL-1, both of which are elevated in some patients with CKD. In mice, TNF-alpha acts directly on adipocytes to release preformed leptin. Endotoxemia and cytokines also induce leptin mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, the presence of inflammation in patients with CKD is likely to be associated with enhanced leptin gene expression. Among patients with ESRD, for example, leptin gene expression is higher in those with elevated C-reactive protein (CRP) levels compared to those with normal CRP levels [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/29\">",
"     29",
"    </a>",
"    ]. This may also be associated with a link among inflammation, enhanced risk of cardiovascular disease, and increased leptin expression [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies consistently show an association between elevated levels of leptin and chronic inflammation, and it has been suggested that leptin may be a negative acute phase reactant in patients with chronic kidney disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bioincompatible hemodialysis membranes, which activate complement and increase cytokine production, are not associated with altered leptin levels, when compared to levels observed with biocompatible membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serial measurement of serum leptin levels among chronic hemodialysis patients found that changes in leptin levels negatively correlated with increases in serum CRP, while a positive correlation was observed with levels of other inflammatory markers, such as serum amyloid A, ceruloplasmin, and interleukin-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/22,48\">",
"       22,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neutrophil chemotaxis is inhibited by increased serum levels of leptin [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hyperinsulinemia and insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance, hyperinsulinemia, and glucose intolerance are well recognized abnormalities in CKD, with hyperinsulinemia possibly associated with increases in leptin levels. The acute and chronic effects of insulin administration were examined in lean and obese men [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/50\">",
"     50",
"    </a>",
"    ]. Although short-term insulin infusion had no effect, long-term (72 hours) infusion significantly increased leptin serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin resistance in patients with normal and decreased renal function is associated with hyperleptinemia, independent of body fat mass [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Among 46 patients with CKD, for example, patients with insulin levels of greater than 14",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    had significantly higher serum leptin levels compared to those with normal insulin levels (38 versus 8",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPERLEPTINEMIA IN RENAL TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considering that the kidneys play a significant role in the metabolism of leptin, it has been hypothesized that renal transplantation should normalize serum leptin. This has been shown in several studies in which elevated serum leptin levels correct to levels similar to healthy controls immediately following successful renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/23,53-55\">",
"     23,53-55",
"    </a>",
"    ]. However, studies have also identified that several months following successful kidney transplantation, serum leptin levels begin to rise compared to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. While the cause of increased serum leptin in long-term follow-up renal transplant patients is unclear, increased adiposity and long-term steroid use likely contribute to elevated leptin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE OF HYPERLEPTINEMIA IN ESRD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein energy wasting, a common problem of patients with advanced CKD, is associated with an increase in morbidity and mortality in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .) However, the mechanism(s) responsible for decreased appetite and caloric intake has not yet been elucidated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several non-leptin related factors appear to contribute to protein energy wasting in the population with ESRD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate protein and caloric intake",
"     </li>",
"     <li>",
"      Increased energy expenditure",
"     </li>",
"     <li>",
"      Hormonal abnormalities",
"     </li>",
"     <li>",
"      Growth factor and insulin resistance",
"     </li>",
"     <li>",
"      Acidosis",
"     </li>",
"     <li>",
"      Inflammation",
"     </li>",
"     <li>",
"      Inadequate dialysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insight into the significance of hyperleptinemia in uremia is provided by findings in knockout mice [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/59\">",
"     59",
"    </a>",
"    ]. Subtotal nephrectomy was performed in leptin receptor-deficient",
"    <span class=\"nowrap\">",
"     db/db",
"    </span>",
"    mice (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Physiologic effects'",
"    </a>",
"    above), hypothalamic melanocortin receptor 4 (MC4-R) knockout mice, and wild-type mice [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/59\">",
"     59",
"    </a>",
"    ]. MC4-R knockout mice were chosen because leptin appears to act centrally via the melanocyte system. Uremia, anorexia, and increased leptin levels were observed in normal mice. By comparison, cachexia was markedly attenuated in both",
"    <span class=\"nowrap\">",
"     db/db",
"    </span>",
"    and MC4-R knockout mice. These results are consistent with the hypothesis that uremia-associated cachexia resulted from increased levels of leptin.",
"   </p>",
"   <p>",
"    Hyperleptinemia is therefore postulated to play a role in anorexia and protein energy wasting associated with end-stage renal disease in patients. However, its clinical significance is unproven, as contradictory findings have been reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study measured serum leptin levels among patients with varying degrees of CKD, some of whom were undergoing maintenance dialysis, and in healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/28\">",
"       28",
"      </a>",
"      ]. An inverse correlation was observed between",
"      <span class=\"nowrap\">",
"       leptin/fat",
"      </span>",
"      mass and dietary intake. Among those with CKD, patients with the highest",
"      <span class=\"nowrap\">",
"       leptin/fat",
"      </span>",
"      mass ratio had lower protein intake and significantly lower lean tissue mass.",
"     </li>",
"     <li>",
"      Similar findings were noted in another report of patients with ESRD in which a significant inverse relationship was observed between",
"      <span class=\"nowrap\">",
"       leptin/body",
"      </span>",
"      fat mass and body weight changes over a 17-month follow-up period [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective observational study of 36 peritoneal dialysis patients, the 25 who lost lean body mass during the year of follow-up had higher baseline CRP levels and a significant increase in serum leptin over time (20.9 to 42.7",
"      <span class=\"nowrap\">",
"       ng/ml)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/60\">",
"       60",
"      </a>",
"      ]. Among the remaining subjects who gained lean body mass during follow-up, there was no significant change in serum leptin levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are consistent with relatively high leptin levels causing weight loss in patients with ESRD. However, another study found no correlation between serum leptin and weight change in patients with hyperleptinemia and ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it has been demonstrated that protein energy wasting is associated with detrimental clinical outcomes in ESRD, the relationship between elevated serum leptin levels and clinical outcomes is not fully defined. One small prospective cohort of 71 hemodialysis patients identified lower baseline serum leptin levels in patients who died within the 81 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33591/abstract/61\">",
"     61",
"    </a>",
"    ]. However, changes in leptin over time were not measured in this study and leptin levels were not normalized to body fat mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90636231\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leptin is the 16,000 Dalton protein product of the obesity gene (ob), which is mainly produced by adipocytes. Leptin may be involved in body weight maintenance in humans. Since the kidneys play a significant role in the removal of leptin from the plasma, serum leptin levels are generally significantly elevated in patients with CKD, particularly when compared to age and body mass index (BMI)-matched controls. Thus, leptin may be related to the anorexia and protein energy wasting frequently observed in those with end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiologic effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Leptin removal by the kidney'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reasons for increased leptin levels relative to body mass in patients with ESRD include loss of renal function, use of low-flow dialyzer membranes, different dialysis modalities, low erythropoietin levels, chronic inflammation, and hyperinsulinemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hyperleptinemia in chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although inconsistently observed, increased leptin levels appear to be associated with impaired nutritional markers and with weight changes in patients with ESRD. Increased leptin levels may contribute to anorexia and protein energy wasting in the ESRD population, but most data are suspect since they are derived from cross-sectional studies.",
"     </li>",
"     <li>",
"      At this time, routine clinical measurements of leptin levels are not recommended. Considering that elevated leptin may contribute to protein energy wasting, management includes maintaining adequate dialysis clearance to adequately remove middle-molecular weight molecules, including leptin. However, while more frequent dialysis, high-flux dialyzers, and hemodiafiltration improve clearance of leptin, these interventions have not yet been demonstrated to improve outcomes. Thus, we do not recommend measures aimed solely at lowering leptin levels. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical significance of hyperleptinemia in ESRD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/1\">",
"      Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/2\">",
"      Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/3\">",
"      Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/4\">",
"      Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/5\">",
"      Sharma K, Considine RV. The Ob protein (leptin) and the kidney. Kidney Int 1998; 53:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/6\">",
"      Caro JF, Sinha MK, Kolaczynski JW, et al. Leptin: the tale of an obesity gene. Diabetes 1996; 45:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/7\">",
"      Cioffi JA, Shafer AW, Zupancic TJ, et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med 1996; 2:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/8\">",
"      Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/9\">",
"      Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/10\">",
"      Caro JF, Kolaczynski JW, Nyce MR, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/11\">",
"      Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/12\">",
"      Meyer C, Robson D, Rackovsky N, et al. Role of the kidney in human leptin metabolism. Am J Physiol 1997; 273:E903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/13\">",
"      Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/14\">",
"      Hama H, Saito A, Takeda T, et al. Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 2004; 145:3935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/15\">",
"      Garibotto G, Russo R, Franceschini R, et al. Inter-organ leptin exchange in humans. Biochem Biophys Res Commun 1998; 247:504.",
"     </a>",
"    </li>",
"    <li>",
"     Jensen, MD, Moller, N, Nair, KS, et al. Regional leptin kinetics in humans. Am J Clin Nutrition 1999: 69:18.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/17\">",
"      Merabet E, Dagogo-Jack S, Coyne DW, et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997; 82:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/18\">",
"      Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/19\">",
"      Briley LP, Szczech LA. Leptin and renal disease. Semin Dial 2006; 19:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/20\">",
"      Howard JK, Lord GM, Clutterbuck EJ, et al. Plasma immunoreactive leptin concentration in end-stage renal disease. Clin Sci (Lond) 1997; 93:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/21\">",
"      Widjaja A, Kielstein JT, Horn R, et al. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease. Nephrol Dial Transplant 2000; 15:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/22\">",
"      Pecoits-Filho R, Nordfors L, Heimb&uuml;rger O, et al. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur J Clin Invest 2002; 32:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/23\">",
"      Landt M, Brennan DC, Parvin CA, et al. Hyperleptinaemia of end-stage renal disease is corrected by renal transplantation. Nephrol Dial Transplant 1998; 13:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/24\">",
"      Odamaki M, Furuya R, Yoneyama T, et al. Association of the serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis 1999; 33:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/25\">",
"      Nishizawa Y, Shoji T, Tanaka S, et al. Plasma leptin level and its relationship with body composition in hemodialysis patients. Am J Kidney Dis 1998; 31:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/26\">",
"      Arkouche W, Juillard L, Delawari E, et al. Peritoneal clearance of leptin in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1999; 34:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/27\">",
"      Landt M, Parvin CA, Dagogo-Jack S, et al. Leptin elimination in hyperleptinaemic peritoneal dialysis patients. Nephrol Dial Transplant 1999; 14:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/28\">",
"      Young GA, Woodrow G, Kendall S, et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant 1997; 12:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/29\">",
"      Nordfors L, L&ouml;nnqvist F, Heimb&uuml;rger O, et al. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/30\">",
"      Heimb&uuml;rger O, L&ouml;nnqvist F, Danielsson A, et al. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/31\">",
"      Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998; 9:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/32\">",
"      Font&aacute;n MP, Rodr&iacute;guez-Carmona A, Cordido F, Garc&iacute;a-Buela J. Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: A comparative analysis. Am J Kidney Dis 1999; 34:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/33\">",
"      Menon V, Wang X, Greene T, et al. Factors associated with serum leptin in patients with chronic kidney disease. Clin Nephrol 2004; 61:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/34\">",
"      Wi��cek A. How does leptin contribute to uraemic cachexia? Nephrol Dial Transplant 2005; 20:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/35\">",
"      Taskapan MC, Taskapan H, Sahin I, et al. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality. Ren Fail 2007; 29:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/36\">",
"      Coyne DW, Dagogo-Jack S, Klein S, et al. High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. Am J Kidney Dis 1998; 32:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/37\">",
"      Mandolfo S, Borlandelli S, Imbasciati E. Leptin and beta2-microglobulin kinetics with three different dialysis modalities. Int J Artif Organs 2006; 29:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/38\">",
"      van Tellingen A, Grooteman MP, Schoorl M, et al. Enhanced long-term reduction of plasma leptin concentrations by super-flux polysulfone dialysers. Nephrol Dial Transplant 2004; 19:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/39\">",
"      Tsujimoto Y, Shoji T, Tabata T, et al. Leptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1999; 34:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/40\">",
"      Mueller WM, Gregoire FM, Stanhope KL, et al. Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. Endocrinology 1998; 139:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/41\">",
"      Teta D, Maillard M, Tedjani A, et al. The effect of pH-neutral peritoneal dialysis fluids on adipokine secretion from cultured adipocytes. Nephrol Dial Transplant 2007; 22:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/42\">",
"      Kokot F, Wiecek A, Mesjasz J, et al. Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant 1998; 13:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/43\">",
"      Axelsson J, Qureshi AR, Heimb&uuml;rger O, et al. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis 2005; 46:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/44\">",
"      Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol 2005; 174:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/45\">",
"      Stenvinkel P, L&ouml;nnqvist F, Schalling M. Molecular studies of leptin: implications for renal disease. Nephrol Dial Transplant 1999; 14:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/46\">",
"      Zoccali C, Tripepi G, Cambareri F, et al. Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. J Ren Nutr 2005; 15:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/47\">",
"      Canivet E, Lavaud S, Wong T, et al. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/48\">",
"      Don BR, Rosales LM, Levine NW, et al. Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int 2001; 59:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/49\">",
"      Ottonello L, Gnerre P, Bertolotto M, et al. Leptin as a uremic toxin interferes with neutrophil chemotaxis. J Am Soc Nephrol 2004; 15:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/50\">",
"      Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes 1996; 45:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/51\">",
"      Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/52\">",
"      Stenvinkel P, Heimb&uuml;rger O, L&ouml;nnqvist F. Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrol Dial Transplant 1997; 12:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/53\">",
"      Kokot F, Adamczak M, Wiecek A. Plasma leptin concentration in kidney transplant patients during the early post-transplant period. Nephrol Dial Transplant 1998; 13:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/54\">",
"      Souza GC, Costa CA, Gon&ccedil;alves LF, Manfro RC. Leptin serum levels in the first year post-renal transplantation. Transplant Proc 2007; 39:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/55\">",
"      Kayacan SM, Yildiz A, Kazancioglu R, et al. The changes in serum leptin, body fat mass and insulin resistance after renal transplantation. Clin Transplant 2003; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/56\">",
"      Kagan A, Haran N, Leschinsky L, et al. Leptin in CAPD patients: serum concentrations and peritoneal loss. Nephrol Dial Transplant 1999; 14:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/57\">",
"      Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/58\">",
"      Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/59\">",
"      Cheung W, Yu PX, Little BM, et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/60\">",
"      Stenvinkel P, Lindholm B, L&ouml;nnqvist F, et al. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33591/abstract/61\">",
"      Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007; 15:1617.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1908 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33591=[""].join("\n");
var outline_f32_51_33591=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90636231\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LEPTIN REMOVAL BY THE KIDNEY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HYPERLEPTINEMIA IN CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Loss of renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemodialysis membranes and dialysis modality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Low erythropoietin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hyperinsulinemia and insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPERLEPTINEMIA IN RENAL TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL SIGNIFICANCE OF HYPERLEPTINEMIA IN ESRD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90636231\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33592="Enteral feeding: Gastric versus post-pyloric";
var content_f32_51_33592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Enteral feeding: Gastric versus post-pyloric",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33592/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33592/contributors\">",
"     Robert Heuschkel, MBBS, MRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33592/contributors\">",
"     Christopher Duggan, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33592/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33592/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33592/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/51/33592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance of appropriate nutrition in patients with acute and chronic illness is well recognized as a fundamental part of standard medical and surgical care. Malnourished patients have poorer clinical outcomes, more complications and infections, and use more resources than well nourished patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Because of lower energy reserves and proportionately higher energy and nutrient needs, children are more susceptible than adults to malnutrition and its multiple complications; as a result, nutritional interventions are even more important in pediatric patients. Thus, in both adult and pediatric patients, every effort should be made to support normal nutritional status throughout illness.",
"   </p>",
"   <p>",
"    Enteral nutrition is generally preferred to parenteral nutrition because of its relative simplicity, safety, and lower cost, as well as its ability to maintain mucosal barrier function. There are several ways to deliver enteral nutrition (",
"    <a class=\"graphic graphic_figure graphicRef68626 \" href=\"UTD.htm?21/41/22175\">",
"     figure 1",
"    </a>",
"    ). This topic review will focus on the theoretical and practical aspects of pre- and post-pyloric enteral nutrition in children and adults. The advantages and disadvantages of each approach will be discussed, with particular reference to the decisions that lead to a choice of feeding method (",
"    <a class=\"graphic graphic_algorithm graphicRef59070 \" href=\"UTD.htm?39/6/40047\">",
"     algorithm 1",
"    </a>",
"    ). The American Gastroenterological Association (AGA) guideline for enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/4\">",
"     4",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISSUES FOR DECIDING UPON THE TYPE OF ENTERAL NUTRITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasoenteric tubes are the first means of gaining enteral access in the vast majority of patients. Orogastric feeds are often used in neonatal practice, since infants are predominantly obligate nasal breathers. A more permanent feeding tube should be considered if enteral support will be needed for more than four to five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=see_link\">",
"     \"Nasogastric and nasoenteric tubes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the transnasal approach may not always be possible. Anatomic anomalies, tumors, and trauma may impede the passage of a tube from the nose into the stomach and can lead to complications (",
"    <a class=\"graphic graphic_table graphicRef78459 \" href=\"UTD.htm?0/39/636\">",
"     table 1",
"    </a>",
"    ). Furthermore, placing a nasoenteric tube may be hazardous in patients with altered consciousness who may not be able to cooperate adequately with swallowing or indicate inadvertent misplacement of the tube into the trachea. Special precautions should be taken particularly in intubated patients, since cuffed endotracheal tubes do not sufficiently protect against pulmonary intubation during passage of a feeding tube. Nasoenteric tubes have also been associated with an increased risk of bacterial sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the above considerations, the following must be established prior to deciding upon the type of access and site of administration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient should be unwilling or unable to maintain adequate nutrition with oral feeds alone. In most cases nutritional support should be considered if recommended daily requirements will not be met for more than about seven days in adults, three to five days in children, and one to three days in infants [",
"      <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/7\">",
"       7",
"      </a>",
"      ]. Earlier intervention is necessary in patients who are already malnourished.",
"     </li>",
"     <li>",
"      There must be a functional gut. The only absolute contraindication to enteral nutrition is mechanical obstruction. Other disease entities (eg, multiple trauma, postoperative state, congenital gastrointestinal anomalies, malabsorption, and short bowel syndrome among others) all require careful management, but are not absolute contraindications to providing enteral nutrition.",
"     </li>",
"     <li>",
"      A route of enteral access must be safely obtainable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GASTRIC FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients tolerate intragastric feeding well. However, it is important to consider the factors that make this possible. The stomach must be structurally and functionally able to act as a reservoir, a propulsive and a digestive organ. Ideally, the lower esophageal sphincter should have adequate tone and function to prevent significant gastroesophageal reflux (GER). Gastric motility should be intact, with coordinated contraction, normal antroduodenal progression, and adequate gastric emptying of liquids. Because this information is usually unavailable, the decision to begin gastric feedings is typically made based upon the history and clinical evaluation. Although most patients can be started on low volume continuous intragastric feeds, a significant history of any of the following would favor starting with jejunal feeding:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent aspiration of gastric contents",
"     </li>",
"     <li>",
"      Esophageal dysmotility with a history of regurgitation",
"     </li>",
"     <li>",
"      Delayed gastric emptying",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial feeding regimen should be dictated by the patient's clinical status. A patient in a stable condition can usually be started on bolus NG feeds, whereas less stable patients may be started with continuous gastric feeds.",
"   </p>",
"   <p>",
"    Feeding tolerance must be continually assessed irrespective of the feeding regimen. Stool frequency, the presence of diarrhea, abdominal distension, urinary output, and vomiting are all factors that may be influenced by the feeding regimen. Diarrhea is commonly described as a complication of any route or type of enteral feeding. There are multiple factors that may precipitate diarrhea in tube-fed patients, not least of which are the patient's primary illness and concomitant medications. The composition, rate, and total volume of the feed may be responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/8\">",
"     8",
"    </a>",
"    ], while contamination of feed by bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/9\">",
"     9",
"    </a>",
"    ] and small bowel bacterial overgrowth may also contribute. Monitoring of gastric residual volumes can also be used to assess tolerance, although a single high residual volume should not lead to unnecessary interruption of feed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Introduction of continuous intragastric feeds is commonly used to assess feeding tolerance, especially if GER is suspected. Patients may be rapidly advanced to bolus feeds once continuous feeds are tolerated at full volume and strength. A more gradual transition to bolus feeds may be necessary in smaller children and in those where upper gastrointestinal motility is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/11\">",
"     11",
"    </a>",
"    ]. It may be necessary to formally assess GER (eg, by esophageal pH or multichannel intraluminal impedance monitoring) in some cases. Since GER often coexists with poor gastric motility in the critically ill, transpyloric feeding is often preferred from the outset in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Role in critically ill patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Advantages of gastric feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric feeding has a number of advantages. It is more physiological, is easier to begin, and more convenient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     More physiological",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intragastric feeding has the clear advantage of providing nutrition by the more physiological route. Intragastric feeds buffer gastric acid better than post-pyloric feedings. In one study, continuous gastric pH measurements among 10 critically ill patients fed intragastrically were greater than 5.0 significantly more often compared to those fed intraduodenally (54 versus 23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, both gastropancreatic reflexes and gastrin release contribute to pancreatic responses prior to food reaching the upper small bowel.",
"   </p>",
"   <p>",
"    The osmolality, pH, and fat content of the substrate reaching the proximal small bowel regulate gastric emptying by both humoral and neural pathways. Bolus intragastric feeding thus more closely mimics physiological normality by allowing intrinsic mechanisms to control delivery of gastric content to the upper small bowel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ease of placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placement of orogastric or nasogastric tubes is a relatively safe procedure, requires minimal training, and is possible at the bedside. Nasogastric tubes are frequently dislodged. The mean life span of a nasal tube has been reported in adults to be only 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/14\">",
"     14",
"    </a>",
"    ]; up to 60 percent of tube removals occur accidentally [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/15\">",
"     15",
"    </a>",
"    ]. Although this underscores their use as short-term devices, they do have a role in the long-term management of some patients.",
"   </p>",
"   <p>",
"    In children requiring nighttime feedings, placement of a new tube every night has been suggested to avoid the daily cosmetic appearance of a nasogastric tube [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/16\">",
"     16",
"    </a>",
"    ]. While complications with insertion do occur [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/5\">",
"     5",
"    </a>",
"    ], the use of softer, more flexible materials has reduced the risks of perforation and local trauma.",
"   </p>",
"   <p>",
"    Assessment of correct positioning by auscultation and aspiration of gastric content is mandatory to help avoid the tracheal instillation of feeds, even if the tube is replaced daily. As mentioned above, placing tubes in patients with altered consciousness is particularly hazardous; thus radiographic confirmation of tube location may be indicated in some clinical settings. Radiologic confirmation of intragastric location is warranted if placement is uncertain or if gastric aspirates show a pH &ge;5.0, since neither capnography nor air insufflation are reliably accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Convenience",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach is able to tolerate a larger volume and higher osmotic load than the upper small intestine. Its role as a reservoir and regulator of food passage into the duodenum gives the patient and clinician much greater flexibility in choosing the type of formula and feeding regimen. The regulation of gastric emptying is complex, yet in health this maintains optimal digestive activity as well as regulating metabolic processes such as glucose homeostasis. Caloric density may be increased more easily to accommodate certain nutritional demands, although the need for maintenance free water must be taken into account for each patient.",
"   </p>",
"   <p>",
"    Gastric feeds allow the option of either bolus or continuous feeds. In the presence of intact physiological mechanisms, bolus feedings are preferable since they minimize disruption to lifestyle and the dependence upon pump devices. Intermittent bolus feeding permits a slower, pump-controlled infusion over several hours and is used as a compromise between rapid, gravity-dependent bolus feeds and continuous infusions. Continuous intragastric feeds may be better tolerated by certain groups of patients (eg, premature infants, patients with mild-moderate GER or mildly delayed gastric emptying). In most instances, isotonic, polymeric feeds are suitable for intragastric feeding. These are cheaper and more widely available than the",
"    <span class=\"nowrap\">",
"     hydrolyzed/elemental",
"    </span>",
"    feeds sometimes used for post-pyloric feeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Disadvantages of gastric feeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main disadvantages of gastric feeding are encountered in patients with delayed gastric emptying and those at risk for aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Delayed gastric emptying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any factor that may delay gastric emptying should be taken into account prior to a trial of intragastric feeds (",
"    <a class=\"graphic graphic_table graphicRef51417 \" href=\"UTD.htm?23/35/24123\">",
"     table 2",
"    </a>",
"    ). Continuous intragastric feeds may be necessary when delayed gastric emptying is suspected. Symptoms such as nausea, vomiting, heartburn, early satiety, belching, and epigastric fullness may all precede actual vomiting as signs of delayed gastric emptying. Treatment with prokinetic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    can be beneficial. In a randomized trial of more than 300 patients, metoclopramide did not reduce the incidence or the long-term mortality from aspiration pneumonias in intragastrically fed patients in the intensive care unit (ICU), although it did delay their onset [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/18\">",
"     18",
"    </a>",
"    ]. The prokinetic drug cisapride is currently only available under restricted access in the United States, and has been withdrawn from use in the UK and Europe, due to concerns about its association with cardiac arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gastroesophageal reflux and aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A poorly functioning lower esophageal sphincter may become even less competent with passage of a nasogastric tube and the onset of gastric feeding. Fine bore tubes cause much less GER and aspiration than large bore tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/19\">",
"     19",
"    </a>",
"    ]. In some settings, it is important to define whether episodes of aspiration are truly gastroesophageal in origin. Aspiration in adults following a stroke, for example, may be due to disordered swallowing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    GER. Oropharyngeal aspiration may be a particular concern in patients with neurogenic dysphagia (such as those with cerebral palsy) and be unrelated to enteral feeding. Videofluoroscopy and isotope salivagrams may help define the source of aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple measures to minimize gastroesophageal reflux should be tried initially in patients suspected of having GER. The head of the bed should be elevated by 30&ordm;, the rate and volume of feeds should be reduced, and their composition modified to a more hydrolyzed or a lower osmolarity formula. The addition of acid blockade and prokinetic agents may also be useful. As mentioned above, significant symptoms of GERD (such as a history of apnea, recurrent aspiration, regurgitation, or moderate to severe esophagitis) would favor a therapeutic trial of post-pyloric feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POST-PYLORIC FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for post-pyloric feedings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary aspiration",
"     </li>",
"     <li>",
"      Severe gastroesophageal reflux (GER) and esophagitis",
"     </li>",
"     <li>",
"      Recurrent emesis",
"     </li>",
"     <li>",
"      Post",
"      <span class=\"nowrap\">",
"       surgery/multiple",
"      </span>",
"      trauma",
"     </li>",
"     <li>",
"      Gastric, antroduodenal dysmotility",
"     </li>",
"     <li>",
"      Patients with decreased bowel sounds and those on paralytic agents. In both settings gastric motility may be impaired more than intestinal motility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Passing a feeding tube beyond the pylorus is necessary in children and adults who are intolerant of intragastric feeds. This is most often due to a combination of GER, poor gastric motility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concerns about pulmonary aspiration. Patients in the ICU are also frequent candidates for post-pyloric feedings due to their underlying illness and frequent finding of gastric ileus. ICU patients have traditionally been supported with parenteral nutrition, but there is an increasing tendency to use post-pyloric feedings instead. In trauma patients, early enteral nutrition is associated with fewer infectious complications than parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A variety of in vitro and in vivo data also support the superiority of enteral over parenteral nutrition in a wide range of critical illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, jejunal feeds have traditionally been elemental or hydrolyzed and less viscous due to the narrow lumen of tubes needed to pass the pylorus, although polymeric feeds have also been tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/26\">",
"     26",
"    </a>",
"    ]. In adults, polymeric formulas are usually used except for those with malabsorptive disorders or pancreatitis. The sudden arrival of a hyperosmolar feed is likely to lead to abdominal cramping, hyperperistalsis, and diarrhea since the jejunum relies on a controlled delivery of isotonic substrate. Thus, jejunal feeds should be administered continuously by pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Advantages of post-pyloric feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jejunal feeding has several advantages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Minimize aspiration risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantage of post-pyloric feeding is that it may reduce the risk of GER and aspiration pneumonia. This was illustrated in a study that included 38 patients who were randomly assigned to feeding by gastric tube or by an endoscopically placed jejunal tube [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/27\">",
"     27",
"    </a>",
"    ]. The jejunally fed group received a significantly higher proportion of their daily calorie intake, had greater increases in their prealbumin levels and had no documented aspirations compared to two aspiration pneumonias seen in the gastrically fed group. See below for discussion of aspiration risk in critical illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Role in critically ill patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-pyloric feeding has theoretical advantages in critically ill patients. Impaired gastric emptying is relatively common and thus feeding beyond the pylorus has the potential to deliver adequate nutrition without the need for parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, compared to gastric feeding, it may reduce the risks associated with high gastric residuals such as aspiration pneumonia. The delivery of a continuous feed to the jejunum also prevents gastric distension, thus potentially allowing for better respiratory function [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/27\">",
"     27",
"    </a>",
"    ]. The main disadvantages are the inconvenience, risks, and costs associated with placement of the tube beyond the pylorus. The rates of complications also depend on the severity of the underlying illness. As an example, prospective data show that critically ill children with shock had a higher incidence of gastrointestinal complications (eg, diarrhea, distension) with post-pyloric feeds than children without shock [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have examined these issues in critically-ill patients; at least three meta-analyses have been published, not all of which reached the same conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Canadian clinical practice guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/31\">",
"     31",
"    </a>",
"    ] noted that small bowel feedings were associated with a lower incidence of pneumonia in critically ill adults (RR 0.77, 95% CI 0.60-1.0), and therefore recommended routine use of small bowel feedings in those centers where this was feasible. Canadian ICUs using these guidelines reported higher rates of adequacy of enteral nutrition (percentage of prescribed energy needs actually received) compared with sites less compliant with these guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, the most recent meta-analysis evaluated potential beneficial and adverse effects in a total of 11 randomized controlled studies comparing gastric versus post-pyloric feeding that enrolled patients who had no evidence of delayed gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/30\">",
"     30",
"    </a>",
"    ]. There were no significant benefits on the risk of diarrhea, length of intensive care unit stay, mortality, or risk of aspiration pneumonia. Furthermore, the gastric feeding group had a much lower risk of experiencing feeding tube placement difficulties or blockage. The authors concluded that early use of post-pyloric feeding instead of gastric feeding in critically ill adults who do not have evidence of impaired gastric emptying (ie, high gastric volumes despite repeated attempts at gastric feeding) was not associated with significant clinical benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Benefits in acute pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;By bypassing the mouth, stomach and duodenum, jejunal feeds minimize the stimulation of pancreatic exocrine secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Accumulating evidence has suggested that post-pyloric feeding is safe and may also reduce complications. The hypothesis underlying this benefit is that enteral nutrients maintain the intestinal barrier. Bacterial translocation from the gut is probably a major cause of infection in the setting of acute pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=see_link\">",
"     \"Pathogenesis of acute pancreatitis\"",
"    </a>",
"    .) In addition, another major advantage of the intestinal route is the elimination of the complications of parenteral nutrition such as catheter sepsis (2 percent even if the catheter is managed appropriately) and less frequent complications such as arterial laceration, pneumothorax, vein thrombosis, thrombophlebitis, hyperglycemia, and catheter embolism. Although the results of large controlled trials are awaited, cautious use of post-pyloric feeds in acute pancreatitis should be strongly considered. A meta-analysis of 27 randomized controlled trials confirmed that enteral nutrition in the setting of acute pancreatitis was associated with significant reductions in length of stay and infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Disadvantages of post-pyloric feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main disadvantages of post-pyloric feeding are related to difficulty with the placement of the tubes, clogging, and maintenance of their proper positions. In practice, success rates at post-pyloric placement can exceed 90 percent, regardless of technique (air insufflation, or use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    as a prokinetic agent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/37\">",
"     37",
"    </a>",
"    ]. Feeding intolerance may also be a problem. A systematic review of transpyloric feeding in preterm infants found no significant growth benefit, but noted an increased mortality rate and an increased rate of feeding cessation due to GI symptoms among those infants assigned to receive transpyloric feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Difficulty with placement and ease of displacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with nasogastric tubes, nasojejunal tubes are very prone to accidental removal. Jejunal tubes are generally of finer bore than gastric tubes and thus frequently occlude, particularly if more viscous feeds and medications are given via this route.",
"   </p>",
"   <p>",
"    Ideal positioning of post-pyloric feeding tubes is into the distal duodenum or jejunum (ie, beyond the ligament of Treitz). An adequately sited post-pyloric tube (verified radiographically) virtually eliminates tracheal aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/27\">",
"     27",
"    </a>",
"    ] and is less likely to become dislodged, even in patients with persistent cough or vomiting. Although feeds can be given through tubes located more proximally in the duodenum, this is not an ideal location: a precise location in the duodenum is difficult to maintain, allows duodenogastric reflux of feed, and hence can contribute to gastroesophageal reflux and aspiration. Tubes in the proximal duodenum may also recoil into the stomach.",
"   </p>",
"   <p>",
"    Intestinal perforation occurs more often with jejunal tubes than with intragastric tubes, although the introduction of softer and more flexible materials reduced the incidence of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Formation of an enterocutaneous fistulae has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/41\">",
"     41",
"    </a>",
"    ]. Most reports of this type of complication have been in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several methods used for placing post-pyloric tubes. Endoscopic placement of a jejunal feeding tube is commonly carried out, and allows placement under direct vision. Fluoroscopy facilitates the placement of jejunal feeding tubes, particularly of gastro-jejunostomy tubes, but requires skilled radiologic support and exposure to radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. More recently, an electromagnetic-guidance technique proved faster (1.7 hours versus 21 hours) and more successful (82 versus 38 percent) than \"blind\" placement of a post-pyloric enteral feeding tube [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/46\">",
"     46",
"    </a>",
"    ]. In general, small-bore tubes are more easily placed than larger tubes.",
"   </p>",
"   <p>",
"    There are several less invasive techniques that have been described. Jejunal tubes with a pH sensitive tip have been successfully passed in children [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/47\">",
"     47",
"    </a>",
"    ]. Weighted tubes have generally been no more successful than unweighted ones [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/48\">",
"     48",
"    </a>",
"    ]. Gastric insufflation of 20 mL of air with an unweighted tube allowed 23 of 25 tubes to be advanced into the small bowel, compared to 11 of 25 in the control group in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/49\">",
"     49",
"    </a>",
"    ]. Other authors have used either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/50\">",
"     50",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/51\">",
"     51",
"    </a>",
"    ] to advance transpyloric tubes with some success. The American Gastroenterological Association (AGA) technical review for enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/5\">",
"     5",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Feeding intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant problem in some patients occurs with rapid entry of formula into the jejunum. This may follow the rapid infusion of feeds via jejunal tubes, or rapid gastric emptying of gastric bolus feeds. These patients develop a \"dumping syndrome\", with symptoms of faintness, palpitations, and sweating, often accompanied by pallor, tachycardia, rebound hypoglycemia, and diarrhea. It usually requires slowing of the rate of feeding or a change in formula. Although whole protein, complex carbohydrate feeds can be infused into the jejunum at low volumes, caloric requirements often require hydrolyzed protein formulas with medium-chain triglycerides and corn",
"    <span class=\"nowrap\">",
"     syrup/glucose",
"    </span>",
"    polymer as sources of fat and carbohydrate, respectively. The addition of complex carbohydrates (eg, cornstarch) can reduce rapid glucose shifts and \"dumping\" symptoms that occur in patients given standard intragastric feeding regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     LONG-TERM PRE- AND POST-PYLORIC FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for pre- and post-pyloric feeding also apply to the more permanent enteral feeding tubes. The placement of a percutaneous endoscopic gastrostomy (PEG) has now become common practice in patients requiring enteral feeding for more than four to five weeks. A feeding jejunostomy tube generally requires surgical placement, although endoscopic placement of jejunostomy tubes has been described (PEJ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. One series in children has found this technique to be feasible in children as young as four years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/57\">",
"     57",
"    </a>",
"    ]. In adults with a BMI &gt;25, the success rates of direct endoscopic jejunostomy placement was lower (67 versus 87 percent) than in patients with a BMI &lt;25, and four out of five serious adverse events occurred in those with a BMI &gt;25 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/58\">",
"     58",
"    </a>",
"    ]. In the presence of any esophageal obstruction, radiological gastrostomy placement has been used with some success [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/59\">",
"     59",
"    </a>",
"    ], although the choice over a surgical gastrostomy clearly depends upon availability of local expertise.",
"   </p>",
"   <p>",
"    Both surgical gastrostomies and PEGs differ from the nasogastric feeding in that they tether the gastric wall to the anterior abdominal wall. This is a particular problem with patients who already have disordered upper gastrointestinal motility. For these patients, the tethering can further worsen gastroesophageal reflux and aspiration. If a motility disorder is strongly suspected, formal motility assessment of the upper GI tract may be carried out prior to the procedure. PEG placement is often combined with a Nissen fundoplication in children with preexisting gastroesophageal reflux disease. If there is significant delay in gastric emptying or disordered antroduodenal motility, placement of a PEJ or surgical jejunostomy may be indicated.",
"   </p>",
"   <p>",
"    In settings where gastrostomy feeds are no longer tolerated, a trial of jejunal feeds can be performed by placing a jejunal tube alongside an existing PEG, or by placing a PEG tube with transgastric jejunostomy tube (PEG-J), through which where a jejunal extension tube allows transpyloric feeding. These techniques provide a short-term feeding solution and may predict the response to a surgical jejunostomy or PEJ. However, they are seldom a long-term solution since these tubes also tend to recoil into the stomach, become clogged, and may be of little value in preventing pre-existing oropharyngeal aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/5,60\">",
"     5,60",
"    </a>",
"    ]. PEJ tubes have significantly better long-term patency and stability of feeding access compared with PEG-J tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33592/abstract/55,61\">",
"     55,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice and route of enteral feeding is based upon the clinical setting, expected duration that support will be required, and assessment of the risk of complications. Enteral rather than parenteral nutrition is preferred in most patients (unless there are specific contraindications) since it is a safer and more physiological means of nutritional support. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Issues for deciding upon the type of enteral nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients can be started on low volume continuous intragastric feeds. However, we suggest beginning with jejunal feeding in patients with any of the following features: recurrent aspiration of gastric contents, esophageal dysmotility with a history of regurgitation, or delayed gastric emptying (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Gastric feeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional settings in which post-pyloric feeding can be considered include: severe gastroesophageal reflux (GER) and esophagitis, recurrent emesis, post",
"      <span class=\"nowrap\">",
"       surgery/multiple",
"      </span>",
"      trauma, gastric, antroduodenal dysmotility, patients with decreased bowel sounds and those on paralytic agents (where gastric motility may be impaired more than intestinal motility). The main disadvantages of post-pyloric feeding are related to difficulty with the placement of the tubes, clogging, and maintenance of their proper positions. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Post-pyloric feeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There continues to be practice variation in use of post-pyloric versus gastric feedings in critically ill patients. In a pediatric ICU, post-pyloric feeding is often used due to relative ease of placement, whereas in many adult ICUs, gastric feedings are often used initially because of the inconvenience of placing and maintaining post-pyloric feeding tubes in older patients.",
"     </li>",
"     <li>",
"      Enteral feeding can be associated with complications. The importance of assessing each individual's risk of GER and possible aspiration pneumonia cannot be overstated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Disadvantages of gastric feeds'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Disadvantages of post-pyloric feeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/1\">",
"      Naber TH, Schermer T, de Bree A, et al. Prevalence of malnutrition in nonsurgical hospitalized patients and its association with disease complications. Am J Clin Nutr 1997; 66:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/2\">",
"      Martyn CN, Winter PD, Coles SJ, Edington J. Effect of nutritional status on use of health care resources by patients with chronic disease living in the community. Clin Nutr 1998; 17:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/3\">",
"      Chima CS, Barco K, Dewitt ML, et al. Relationship of nutritional status to length of stay, hospital costs, and discharge status of patients hospitalized in the medicine service. J Am Diet Assoc 1997; 97:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/4\">",
"      American Gastroenterological Association Medical Position Statement: guidelines for the use of enteral nutrition. Gastroenterology 1995; 108:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/5\">",
"      Kirby DF, Delegge MH, Fleming CR. American Gastroenterological Association technical review on tube feeding for enteral nutrition. Gastroenterology 1995; 108:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/6\">",
"      George DL, Falk PS, Umberto Meduri G, et al. Nosocomial sinusitis in patients in the medical intensive care unit: a prospective epidemiological study. Clin Infect Dis 1998; 27:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/7\">",
"      Cunningham JJ. Body composition and nutrition support in pediatrics: what to defend and how soon to begin. Nutr Clin Pract 1995; 10:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/8\">",
"      Hiebert JM, Brown A, Anderson RG, et al. Comparison of continuous vs intermittent tube feedings in adult burn patients. JPEN J Parenter Enteral Nutr 1981; 5:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/9\">",
"      Oie S, Kamiya A, Hironaga K, Koshiro A. Microbial contamination of enteral feeding solution and its prevention. Am J Infect Control 1992; 20:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/10\">",
"      McClave SA, Snider HL, Lowen CC, et al. Use of residual volume as a marker for enteral feeding intolerance: prospective blinded comparison with physical examination and radiographic findings. JPEN J Parenter Enteral Nutr 1992; 16:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/11\">",
"      Powers T, Cowan GS Jr, Deckard M, Stark N. Prospective randomized evaluation of two regimens for converting from continuous to intermittent feedings in patients with feeding gastrostomies. JPEN J Parenter Enteral Nutr 1991; 15:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/12\">",
"      Dunham CM, Frankenfield D, Belzberg H, et al. Gut failure--predictor of or contributor to mortality in mechanically ventilated blunt trauma patients? J Trauma 1994; 37:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/13\">",
"      Valentine RJ, Turner WW Jr, Borman KR, Weigelt JA. Does nasoenteral feeding afford adequate gastroduodenal stress prophylaxis? Crit Care Med 1986; 14:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/14\">",
"      Mathus-Vliegen EM, Tytgat GN, Merkus MP. Feeding tubes in endoscopic and clinical practice: the longer the better? Gastrointest Endosc 1993; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/15\">",
"      Silk DB, Rees RG, Keohane PP, Attrill H. Clinical efficacy and design changes of \"fine bore\" nasogastric feeding tubes: a seven-year experience involving 809 intubations in 403 patients. JPEN J Parenter Enteral Nutr 1987; 11:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/16\">",
"      Beattie RM, Schiffrin EJ, Donnet-Hughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994; 8:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/17\">",
"      Elpern EH, Killeen K, Talla E, et al. Capnometry and air insufflation for assessing initial placement of gastric tubes. Am J Crit Care 2007; 16:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/18\">",
"      Yavagal DR, Karnad DR, Oak JL. Metoclopramide for preventing pneumonia in critically ill patients receiving enteral tube feeding: a randomized controlled trial. Crit Care Med 2000; 28:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/19\">",
"      Ib&aacute;&ntilde;ez J, Pe&ntilde;afiel A, Mars&eacute; P, et al. Incidence of gastroesophageal reflux and aspiration in mechanically ventilated patients using small-bore nasogastric tubes. JPEN J Parenter Enteral Nutr 2000; 24:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/20\">",
"      Heyman S. The radionuclide salivagram for detecting the pulmonary aspiration of saliva in an infant. Pediatr Radiol 1989; 19:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/21\">",
"      Misra S, Macwan K, Albert V. Transpyloric feeding in gastroesophageal-reflux-associated apnea in premature infants. Acta Paediatr 2007; 96:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/22\">",
"      Kudsk KA. Gut mucosal nutritional support--enteral nutrition as primary therapy after multiple system trauma. Gut 1994; 35:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/23\">",
"      Moore FA, Moore EE, Jones TN, et al. TEN versus TPN following major abdominal trauma--reduced septic morbidity. J Trauma 1989; 29:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/24\">",
"      Heyland DK, Cook DJ, Guyatt GH. Does the formulation of enteral feeding products influence infectious morbidity and mortality rates in the critically ill patients? A critical review of the evidence. Crit Care Med 1994; 22:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/25\">",
"      Hadfield RJ, Sinclair DG, Houldsworth PE, Evans TW. Effects of enteral and parenteral nutrition on gut mucosal permeability in the critically ill. Am J Respir Crit Care Med 1995; 152:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/26\">",
"      Ford EG, Hull SF, Jennings LM, Andrassy RJ. Clinical comparison of tolerance to elemental or polymeric enteral feedings in the postoperative patient. J Am Coll Nutr 1992; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/27\">",
"      Montecalvo MA, Steger KA, Farber HW, et al. Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. The Critical Care Research Team. Crit Care Med 1992; 20:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/28\">",
"      Montejo JC. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. The Nutritional and Metabolic Working Group of the Spanish Society of Intensive Care Medicine and Coronary Units. Crit Care Med 1999; 27:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/29\">",
"      L&oacute;pez-Herce J, Menc&iacute;a S, S&aacute;nchez C, et al. Postpyloric enteral nutrition in the critically ill child with shock: a prospective observational study. Nutr J 2008; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/30\">",
"      Ho KM, Dobb GJ, Webb SA. A comparison of early gastric and post-pyloric feeding in critically ill patients: a meta-analysis. Intensive Care Med 2006; 32:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/31\">",
"      Heyland DK, Dhaliwal R, Drover JW, et al. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 2003; 27:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/32\">",
"      Marik PE, Zaloga GP. Gastric versus post-pyloric feeding: a systematic review. Crit Care 2003; 7:R46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/33\">",
"      Heyland DK, Dhaliwal R, Day A, et al. Validation of the Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients: results of a prospective observational study. Crit Care Med 2004; 32:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/34\">",
"      Ragins H, Levenson SM, Signer R, et al. Intrajejunal administration of an elemental diet at neutral pH avoids pancreatic stimulation. Studies in dog and man. Am J Surg 1973; 126:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/35\">",
"      Wolfe BM, Keltner RM, Kaminski DL. The effect of an intraduodenal elemental diet on pancreatic secretion. Surg Gynecol Obstet 1975; 140:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/36\">",
"      McClave SA, Chang WK, Dhaliwal R, Heyland DK. Nutrition support in acute pancreatitis: a systematic review of the literature. JPEN J Parenter Enteral Nutr 2006; 30:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/37\">",
"      Phipps LM, Weber MD, Ginder BR, et al. A randomized controlled trial comparing three different techniques of nasojejunal feeding tube placement in critically ill children. JPEN J Parenter Enteral Nutr 2005; 29:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/38\">",
"      McGuire W, McEwan P. Transpyloric versus gastric tube feeding for preterm infants. Cochrane Database Syst Rev 2007; :CD003487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/39\">",
"      Chen JW, Wong PW. Intestinal complications of nasojejunal feeding in low-birth-weight infants. J Pediatr 1974; 85:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/40\">",
"      McAlister WH, Siegel MJ, Shackelford GD, et al. Intestinal perforations by tube feedings in small infants: clinical and experimental studies. AJR Am J Roentgenol 1985; 145:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/41\">",
"      Patrick CH, Goodin J, Fogarty J. Complication of prolonged transpyloric feeding: formation of an enterocutaneous fistula. J Pediatr Surg 1988; 23:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/42\">",
"      Laing IA, Lang MA, Callaghan O, Hume R. Nasogastric compared with nasoduodenal feeding in low birthweight infants. Arch Dis Child 1986; 61:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/43\">",
"      Mulla M, Mitchell I. Transpyloric feeding in the newborn: use in neonates with and without respiratory failure. Scott Med J 1983; 28:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/44\">",
"      Pobiel RS, Bisset GS 3rd, Pobiel MS. Nasojejunal feeding tube placement in children: four-year cumulative experience. Radiology 1994; 190:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/45\">",
"      Prager R, Laboy V, Venus B, Mathru M. Value of fluoroscopic assistance during transpyloric intubation. Crit Care Med 1986; 14:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/46\">",
"      October TW, Hardart GE. Successful placement of postpyloric enteral tubes using electromagnetic guidance in critically ill children. Pediatr Crit Care Med 2009; 10:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/47\">",
"      Dimand RJ, Veereman-Wauters G, Braner DA. Bedside placement of pH-guided transpyloric small bowel feeding tubes in critically ill infants and small children. JPEN J Parenter Enteral Nutr 1997; 21:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/48\">",
"      Lord LM, Weiser-Maimone A, Pulhamus M, Sax HC. Comparison of weighted vs unweighted enteral feeding tubes for efficacy of transpyloric intubation. JPEN J Parenter Enteral Nutr 1993; 17:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/49\">",
"      Spalding HK, Sullivan KJ, Soremi O, et al. Bedside placement of transpyloric feeding tubes in the pediatric intensive care unit using gastric insufflation. Crit Care Med 2000; 28:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/50\">",
"      Stern MA, Wolf DC. Erythromycin as a prokinetic agent: a prospective, randomized, controlled study of efficacy in nasoenteric tube placement. Am J Gastroenterol 1994; 89:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/51\">",
"      Heiselman DE, Hofer T, Vidovich RR. Enteral feeding tube placement success with intravenous metoclopramide administration in ICU patients. Chest 1995; 107:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/52\">",
"      Borovoy J, Furuta L, Nurko S. Benefit of uncooked cornstarch in the management of children with dumping syndrome fed exclusively by gastrostomy. Am J Gastroenterol 1998; 93:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/53\">",
"      Shike M, Latkany L. Direct percutaneous endoscopic jejunostomy. Gastrointest Endosc Clin N Am 1998; 8:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/54\">",
"      Dumot JA, Seidner DL. Direct button percutaneous endoscopic jejunostomy: successful placement in a patient with severe malnutrition and previous gastric resection. Gastrointest Endosc 1997; 45:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/55\">",
"      Fan AC, Baron TH, Rumalla A, Harewood GC. Comparison of direct percutaneous endoscopic jejunostomy and PEG with jejunal extension. Gastrointest Endosc 2002; 56:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/56\">",
"      Bueno JT, Schattner MA, Barrera R, et al. Endoscopic placement of direct percutaneous jejunostomy tubes in patients with complications after esophagectomy. Gastrointest Endosc 2003; 57:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/57\">",
"      Virnig DJ, Frech EJ, Delegge MH, Fang JC. Direct percutaneous endoscopic jejunostomy: a case series in pediatric patients. Gastrointest Endosc 2008; 67:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/58\">",
"      Mackenzie SH, Haslem D, Hilden K, et al. Success rate of direct percutaneous endoscopic jejunostomy in patients who are obese. Gastrointest Endosc 2008; 67:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/59\">",
"      Brown AS, Mueller PR, Ferrucci JT Jr. Controlled percutaneous gastrostomy: nylon T-fastener for fixation of the anterior gastric wall. Radiology 1986; 158:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/60\">",
"      Lazarus BA, Murphy JB, Culpepper L. Aspiration associated with long-term gastric versus jejunal feeding: a critical analysis of the literature. Arch Phys Med Rehabil 1990; 71:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33592/abstract/61\">",
"      Raval MV, Phillips JD. Optimal enteral feeding in children with gastric dysfunction: surgical jejunostomy vs image-guided gastrojejunal tube placement. J Pediatr Surg 2006; 41:1679.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2583 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33592=[""].join("\n");
var outline_f32_51_33592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISSUES FOR DECIDING UPON THE TYPE OF ENTERAL NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GASTRIC FEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Advantages of gastric feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - More physiological",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ease of placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Convenience",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Disadvantages of gastric feeds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gastroesophageal reflux and aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POST-PYLORIC FEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Advantages of post-pyloric feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Minimize aspiration risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Role in critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Benefits in acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Disadvantages of post-pyloric feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Difficulty with placement and ease of displacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Feeding intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      LONG-TERM PRE- AND POST-PYLORIC FEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2583\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2583|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/6/40047\" title=\"algorithm 1\">",
"      Enteral tube feeding algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2583|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/41/22175\" title=\"figure 1\">",
"      AGA Nasoenteric routes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2583|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/39/636\" title=\"table 1\">",
"      Nasoenteric tube complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/35/24123\" title=\"table 2\">",
"      Causes of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9480?source=related_link\">",
"      Nasogastric and nasoenteric tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44774?source=related_link\">",
"      Pathogenesis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33593="Overview of the management of chronic mitral regurgitation";
var content_f32_51_33593=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of chronic mitral regurgitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33593/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33593/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33593/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33593/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/51/33593/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/51/33593/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/51/33593/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern management of patients with chronic mitral regurgitation (MR) requires an understanding of multiple factors: These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pathophysiology and natural history of the disease",
"     </li>",
"     <li>",
"      The severity of the valvular lesion",
"     </li>",
"     <li>",
"      The development of atrial fibrillation",
"     </li>",
"     <li>",
"      The therapeutic potential of chronic vasodilator therapy",
"     </li>",
"     <li>",
"      The indications for endocarditis prophylaxis",
"     </li>",
"     <li>",
"      The indications for mitral valve repair and mitral valve replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While our knowledge of these areas is not yet complete, it is possible to develop a rational plan for the management of patients with chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These management issues will be reviewed here. The management of functional and ischemic MR is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elusive and poorly understood aspect of the pathophysiology of MR is the nature of the transition from the chronic compensated stage to a decompensated stage. This evolution generally occurs over many years, even decades, depending upon the severity of the regurgitant lesion and the cardiovascular response to the regurgitant volume. The etiology of MR also plays a role in the natural history of this process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stages of MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular (LV) chamber size and function have been used to define a compensated, transitional, and decompensated stage in patients with chronic MR (",
"    <a class=\"graphic graphic_table graphicRef79918 \" href=\"UTD.htm?34/11/35003\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=see_link\">",
"     \"Pathophysiology and stages of chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The compensated stage is defined largely on the basis of natural history and other data that indicate a benign prognosis when the end-diastolic dimension is less than 60 mm and the end-systolic dimension is less than 40 mm (as measured by echocardiography).",
"     </li>",
"     <li>",
"      The natural history of the",
"      <strong>",
"       transitional",
"      </strong>",
"      stage is not precisely defined, but most published data indicate that a good clinical result can be achieved if surgery is performed at this time.",
"     </li>",
"     <li>",
"      The decompensated stage is based upon data derived from patients who have undergone valvular surgery, which indicates that patients who exhibit one or more markers of a decompensated ventricle are at risk for a poor or suboptimal clinical result after valve replacement. These markers include LV end-diastolic dimension greater than 70 mm, LV end-systolic dimension greater than 45 to 47 mm, or a left ventricular ejection fraction (LVEF) less than 50 to 55 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link&amp;anchor=H8#H8\">",
"       \"Indications for corrective surgery in severe chronic primary mitral regurgitation\", section on 'Reduced left ventricular function'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these considerations do not identify the optimal time for mitral valve replacement or repair, they do enable the clinician to predict a poor LV response to corrective surgery and, in this fashion, provide a picture of the options of surgical or nonsurgical treatment. In principle, corrective surgery should be performed during the transition from a compensated to decompensated stage of the disease (ie, before the decompensated stage is established). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Mitral valve surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Early identification of progression avoids the development of irreversible changes in LV function that may preclude an optimal response to corrective surgery. Patients with chronic MR and severe LV dysfunction (eg, LVEF &lt;40 percent) are at very high risk of a suboptimal postoperative result. Many of these patients exhibit characteristics of a dilated cardiomyopathy with increased LV afterload and depressed myocardial contractility. Their initial management includes aggressive medical therapy with digitalis, diuretics, and vasodilators.",
"   </p>",
"   <p>",
"    Cardiac catheterization and coronary angiography should be performed in preparation for surgery. Corrective surgery (and continued medical therapy) generally provides symptomatic relief, but chamber enlargement and a low LVEF usually persist despite technically successful surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Etiology of mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of MR are primary diseases of the valve leaflets (eg, mitral valve prolapse and, in developing countries, rheumatic heart disease) and secondary MR due to cardiomyopathy or coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best natural history data that are currently available have come from studies of patients with mitral valve prolapse and flail mitral valve leaflet. It is generally assumed that these findings may be applied to MR of other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the following factors may be useful for stratifying patients into groups that can be managed medically versus those that require surgical intervention. Older age, male gender, and auscultatory evidence of severe MR are prognostic clues that identify patients with mitral valve prolapse who are at a relatively high risk of complications. Echocardiographic evidence of LV enlargement provides further evidence of high risk that requires careful follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     MR due to flail leaflet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe MR due to a flail leaflet, an LVEF &lt;60 percent, and presence of symptoms are predictive of excess mortality. The risk of death was reduced by mitral valve surgery (adjusted hazard ratio 0.42, 95% CI 0.21-0.84) in a series of 394 patients of varying baseline symptom status (36 percent with severe symptoms). For asymptomatic patients with flail leaflet and severe MR (as for other asymptomatic patients with severe MR), surgical correction should be considered early in the course of the disease if valve repair is feasible with a &gt;90 percent likelihood of success. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H24\">",
"     'Mitral valve surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic MR is usually well tolerated during pregnancy. The normal fall in systemic vascular resistance tends to reduce the degree of regurgitation. Issues related to the management of mitral regurgitation during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link&amp;anchor=H12#H12\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\", section on 'Effect of pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION OF MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the stage of MR (",
"    <a class=\"graphic graphic_table graphicRef79918 \" href=\"UTD.htm?34/11/35003\">",
"     table 1",
"    </a>",
"    ), decisions regarding the timing of surgery depend upon the severity of MR. This can be assessed by both clinical and echocardiographic criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe chronic MR often experience exercise intolerance, dyspnea, or fatigue during the transition from a compensated to a decompensated stage. Because of the importance of identifying such a transition, a careful history is important to establish an estimate of baseline exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most experts and the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend that patients with chronic MR who become symptomatic are candidates for corrective mitral surgery, even if the symptoms improve with medical therapy or the left ventricle appears to be compensated (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 2A",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. If there is uncertainty about the presence or absence of symptoms, exercise testing may provide objective information that may not be available from the medical history alone. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There has traditionally been reluctance to treat asymptomatic patients with chronic MR surgically. With nothing to gain in the way of symptomatic improvement, early surgery exposes the patient to perioperative morbidity and mortality as well as the long-term complications of a prosthetic valve if a valve repair procedure cannot be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, there may be benefit from surgery prior to the onset of symptoms. As an example, left ventricular decompensation may develop in the setting of severe MR despite the absence of symptoms. Thus, waiting for the patient to experience dyspnea or exercise intolerance may allow time for the development of irreversible depression of LV function. For this reason, it is important to have an objective measure of LV function in patients with asymptomatic MR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of MR can be assessed semiquantitatively by Doppler echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Transthoracic echocardiography usually provides the desired information and is generally preferred to transesophageal echocardiography because it is noninvasive (",
"    <a class=\"graphic graphic_table graphicRef68474 \" href=\"UTD.htm?3/34/3628\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63907 \" href=\"UTD.htm?30/15/30971\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Based upon the 2003 American Society of Echocardiography guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/11\">",
"     11",
"    </a>",
"    ], the following findings, in order or priority, are consistent with severe MR (",
"    <a class=\"graphic graphic_table graphicRef77111 \" href=\"UTD.htm?34/46/35564\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A vena contracta width &ge;7 mm",
"     </li>",
"     <li>",
"      A regurgitant orifice area &ge;0.40 cm2",
"     </li>",
"     <li>",
"      A regurgitant volume &ge;60 mL",
"     </li>",
"     <li>",
"      A regurgitant fraction &ge;50 percent",
"     </li>",
"     <li>",
"      A jet area &gt;40 percent of left atrial area, but this is not so reproducible and less often used",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These values are based on an average adult size and may need to be adjusted for body size in small or large patients; however, there is no specific formula for making this adjustment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\", section on 'Severity of mitral regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of echo-Doppler grading, severe chronic MR does NOT exist (with rare exceptions) without clear evidence of left atrial or left ventricular enlargement. If the left ventricular end-diastolic dimension (by echocardiography) is less than 60 mm (approximately 35",
"    <span class=\"nowrap\">",
"     mm/m2),",
"    </span>",
"    the diagnosis of severe chronic MR should be seriously questioned. Left atrial size may reflect the \"history\" (severity and duration) of chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac catheterization is primarily indicated when echocardiography does not provide diagnostic information or the echocardiographic findings are discrepant from the clinical features (",
"    <a class=\"graphic graphic_table graphicRef55552 \" href=\"UTD.htm?37/11/38075\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Serial monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the initial evaluation, serial monitoring is warranted in patients with chronic MR. The goals of monitoring are to assess changes in clinical status by history and physical examination and to assess changes in left ventricular function, which can occur in the absence of symptoms, by echocardiography.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines included recommendations for clinical and transthoracic echocardiographic monitoring in asymptomatic patients with chronic MR (",
"    <a class=\"graphic graphic_table graphicRef68474 \" href=\"UTD.htm?3/34/3628\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]. Echocardiography is performed to assess the left ventricular ejection fraction and end-systolic dimension.",
"   </p>",
"   <p>",
"    The recommendations varied with the severity of MR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild MR and no evidence of left ventricular enlargement, left ventricular dysfunction, or pulmonary hypertension should be seen yearly for history and physical examination with instructions to contact the physician if symptoms occur. Repeat echocardiography at these visits is not necessary in the absence of clinical evidence of worsening MR.",
"     </li>",
"     <li>",
"      Patients with moderate MR should be seen yearly or sooner if symptoms occur. Repeat transthoracic echocardiography should be obtained at these visits.",
"     </li>",
"     <li>",
"      Patients with severe MR should be seen every 6 to 12 months or sooner if symptoms occur. Repeat transthoracic echocardiography should be obtained at these visits. The six month interval is preferred if stability has not been documented, there is evidence of progression, or measurements are close to the echocardiographic cutoff values for mitral valve surgery (",
"      <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"       table 2A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"       \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercise stress testing may add objective evidence about symptoms and a change in exercise tolerance; it may be particularly useful if a good history of exercise capacity is difficult to obtain. Measurement of MR severity and pulmonary artery pressure during exercise also may be helpful.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography is NOT indicated for routine follow-up (",
"    <a class=\"graphic graphic_table graphicRef63907 \" href=\"UTD.htm?30/15/30971\">",
"     table 4",
"    </a>",
"    ). It does, however, have a role in preoperative and intraoperative evaluation when mitral valve surgery is being considered.",
"   </p>",
"   <p>",
"    A separate issue, the indications for repeat echocardiography in patients with mitral valve prolapse independent of MR, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link&amp;anchor=H10#H10\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14009091\">",
"    <span class=\"h2\">",
"     Natriuretic peptide levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum BNP may have prognostic value in patients with chronic mitral regurgitation. An initial report evaluated 124 patients with chronic MR, 94 with mitral valve prolapse; almost all patients were asymptomatic or had only a mild limitation in physical activity and the mean left ventricular ejection fraction was 69 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/13\">",
"     13",
"    </a>",
"    ]. Serum BNP values &ge;31",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    predicted lower five-year survival (72 versus 96 percent) and were independently predictive of mortality. BNP activation reflected the clinical consequences of MR rather than the severity of MR. N-terminal pro-BNP has also been associated with markers of LV remodeling and functional capacity in patients with chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY AND EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise has a variable effect on the regurgitant fraction in patients with chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/16\">",
"     16",
"    </a>",
"    ]. The reduction in systemic vascular resistance may result in no change or a mild reduction in the regurgitant fraction. On the other hand, an elevation in blood pressure, as occurs with static exercise, can lead to marked increases in regurgitant volume and pulmonary capillary pressure.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that there are no exercise restrictions in asymptomatic patients who are in sinus rhythm and have normal left ventricular and left atrial dimensions and a normal pulmonary artery pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]. Specific recommendations for participation in competitive sports in patients with MR were made by the 36th Bethesda Conference [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/16\">",
"     16",
"    </a>",
"    ], which also included a classification of sports (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild to moderate MR who are in sinus rhythm, have normal left ventricular size and function, and normal pulmonary artery pressures can participate in all competitive sports.",
"     </li>",
"     <li>",
"      Patients with mild to moderate MR who are in sinus rhythm, have normal left ventricular systolic function at rest, and mild left ventricular enlargement can participate in low and moderate static and all dynamic competitive sports (class IA, IB, IIA, IIB, and IIC) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with severe MR and definite left ventricular enlargement, pulmonary hypertension, or any reduction in left ventricular systolic function at rest should not participate in any competitive sports.",
"     </li>",
"     <li>",
"      Patients with atrial fibrillation or a history of atrial fibrillation who are treated with long-term anticoagulation therapy should not engage in sports with any for bodily contact or risk of trauma (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for exercise after mitral repair for chronic MR are described below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Exercise after valve repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ATRIAL ENLARGEMENT AND FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic MR is often complicated by the development of left atrial enlargement and atrial fibrillation (AF), both of which can have an impact on patient outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the ventricle is compensated and the heart rate is not excessive, the patient with AF merely notices palpitations. There is little or no disability in these cases except for an increased risk of stroke or other sign of systemic embolization. These patients are candidates for direct current cardioversion and antiarrhythmic drug therapy to maintain sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It can be argued, however, that mitral valve surgery should be performed before AF is persistent or resistant to cardioversion. This notion is based upon the observation that persistent AF after surgery places the patient at particularly high risk for atrial thrombus and arterial embolism.",
"   </p>",
"   <p>",
"    Preoperative variables that are associated with the persistence of AF after surgery are a prolonged duration of the arrhythmia (exceeding one year) and moderate to severe left atrial enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/12,18,19\">",
"     12,18,19",
"    </a>",
"    ]. When the preoperative left atrial size exceeds 50 mm (by echocardiography), fewer than one-half of the patients return to normal sinus rhythm after surgery; in contrast, when left atrial dimension is normal, 85 percent of patients return to normal sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data and anecdotal clinical experience support the concept that, if postoperative AF and its complications are to be minimized, corrective surgery should be considered within months of the development of AF or before substantial left atrial enlargement is present. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the weight of evidence was in favor of the efficacy of mitral valve surgery in asymptomatic patients with severe chronic MR and preserved left ventricular function who have new onset AF (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"     table 2A",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]. The 2007 ESC guidelines thought that this was a debatable point [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although AF is not necessarily an indication for surgery in an asymptomatic patient with preserved left ventricular function, the burden of this arrhythmia in a patient with borderline left ventricular function (LVEF 55 to 60 percent) might be used as an indication for surgery, especially if the risk of surgery is low and the valve appears to be amenable to repair. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Mitral valve replacement versus repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of the maze procedure or radiofrequency or cryoablation as an adjunct to mitral valve repair or replacement is an effective approach to reduce the incidence of postoperative AF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Left atrial enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left atrial enlargement itself, in the absence of AF, may be a risk factor for an adverse outcome following mitral valve surgery. In one study, for example, measures of left ventricular systolic function and left atrial size were equally important in predicting postoperative cardiac-related mortality in patients with symptomatic chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/12\">",
"     12",
"    </a>",
"    ]. The authors concluded that left atrial size may reflect the \"history\" (severity and duration) of MR. This observation again supports the notion that surgery should be considered prior to the development of significant left atrial enlargement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     USE OF VASODILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for vasodilator therapy in patients with chronic MR depend upon the presence or absence of symptoms and the functional state of the left ventricle. These issues are discussed in detail elsewhere and will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=see_link\">",
"     \"Vasodilator therapy in chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published studies that support the hypothesis that vasodilator therapy is beneficial in asymptomatic patients with chronic MR. In addition, the administration of vasodilators in patients with normal LV function might limit the development of symptoms due to increasing LV dysfunction, thereby masking an indication for surgery. Thus, with some exceptions (eg, the hypertensive patient), vasodilators are",
"    <strong>",
"     not",
"    </strong>",
"    recommended for use in asymptomatic patients with chronic MR due to primary valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies confirm a beneficial effect of",
"    <strong>",
"     acute",
"    </strong>",
"    vasodilator therapy in patients with chronic MR. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , for example, decreases left ventricular end-diastolic pressure and volume while increasing forward stroke volume and cardiac index.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    has similar salutary effects. In contrast, the acute effect of angiotensin converting enzyme (ACE) inhibitors or nitrates is usually a decrease or no change in the cardiac index.",
"   </p>",
"   <p>",
"    Data regarding the",
"    <strong>",
"     chronic",
"    </strong>",
"    effect of vasodilators are less impressive. Chronic therapy provides the most benefit for patients with the largest hearts, the poorest systolic function, and the most disabling symptoms. When combined with digitalis and diuretics, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    can produce substantial symptomatic and hemodynamic improvement in patients who are in NYHA functional class II-IV [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/20\">",
"     20",
"    </a>",
"    ]. ACE inhibitors may also be beneficial in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/21\">",
"     21",
"    </a>",
"    ]. However, because of the substantial improvement in outcome associated with surgery in patients with symptomatic MR, chronic vasodilator therapy is only indicated in those who are not surgical candidates.",
"   </p>",
"   <p>",
"    In patients for whom chronic vasodilator therapy is warranted, the following recommendations can be made based upon the etiology of MR and whether or not the patient is a candidate for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=see_link\">",
"     \"Vasodilator therapy in chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In symptomatic patients with primary MR (eg, myxomatous or rheumatic), there is little potential to induce a change in the regurgitant orifice area via preload reduction and the therapeutic goal should be a reduction in systolic pressure. Thus, a beta blocker, diuretic,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , or calcium channel blocker should be used. However, medical therapy is not a substitute for surgical intervention in patients with chronic symptomatic MR.",
"     </li>",
"     <li>",
"      Chronic vasodilator therapy is indicated in symptomatic patients who are not candidates for surgery. The evidence of benefit is best in patients with secondary (functional) MR due to left ventricular dysfunction. Treatment of such patients should consist of optimal medical therapy of heart failure and, in appropriate patients, cardiac resynchronization therapy. With respect to ACE inhibitors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiotensin II receptor blockers, the dose titration and monitoring schedules are the same as for heart failure due to left ventricular systolic dysfunction in the absence of moderate to severe MR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"       \"Functional mitral regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CARDIAC RESYNCHRONIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected patients with functional MR, cardiac resynchronization therapy (CRT) with biventricular pacing may be helpful. At this time, however, standard indications for CRT in patients with heart failure are based upon left ventricular (LV) function, functional class, and measures of LV dyssynchrony. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link&amp;anchor=H10#H10\">",
"     \"Functional mitral regurgitation\", section on 'Cardiac resynchronization therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of an embolic event is increased in patients with rheumatic or nonrheumatic MR, particularly when atrial fibrillation is also present.",
"   </p>",
"   <p>",
"    The presence of mitral annular calcification, which is often associated with MR, increases the risk of embolism, even in the absence of atrial fibrillation. Mitral annular calcification, risk of stroke and recommendations for treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=see_link\">",
"     \"Mitral annular calcification\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following recommendations generally agree with the recommendations for antithrombotic therapy in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular disease guidelines and the 2008 Eighth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombotic Therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1,22\">",
"     1,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rheumatic mitral valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the recommendation in the 2008 ACCP guidelines that anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.5, range 2.0 to 3.0) is indicated in patients with rheumatic mitral valve disease who have a history of systemic embolism, left atrial thrombus, or paroxysmal or chronic atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/22\">",
"     22",
"    </a>",
"    ]. The 2006 AHA guidelines also recommend anticoagulation in patients with mitral regurgitation and atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with rheumatic mitral valve disease and atrial fibrillation with recurrent systemic embolism despite adequate anticoagulation, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/22\">",
"     22",
"    </a>",
"    ]. An alternative strategy might be the adjustment of anticoagulant doing to achieve a higher target INR (target INR 3.0, range 2.5 to 3.5)",
"   </p>",
"   <p>",
"    One exception to our general agreement with the 2008 ACCP guidelines is that we do NOT generally suggest anticoagulation for patients with rheumatic heart disease and left atrial diameter &gt;55 mm in the absence of other indication for anticoagulation. In the 2008 ACCP guidelines, anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.5, range 2.0 to 3.0) is suggested for patients with left atrial diameter &gt;55 mm and rheumatic mitral valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/22\">",
"     22",
"    </a>",
"    ]. This suggestion places a relatively high value on prevention of systemic embolism and a relatively low value on avoiding the bleeding risk and inconvenience associated with anticoagulation therapy.",
"   </p>",
"   <p>",
"    Data are lacking to support the use of direct thrombin inhibitors in patients with valve disease and atrial fibrillation. Therefore, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    in the setting of rheumatic mitral valve disease and atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nonrheumatic MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.5, range 2.0 to 3.0) is recommended in patients with nonrheumatic MR who have atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ] or a history of systemic embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mitral valve prolapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for antithrombotic therapy in patients with mitral valve prolapse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=see_link\">",
"     \"Nonarrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA guidelines on infective endocarditis and the 2008",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    guideline update on valvular heart disease revised prior recommendations for patients with acquired valvular disease, including those with chronic MR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As a result, antibiotic prophylaxis is",
"    <strong>",
"     no longer",
"    </strong>",
"    recommended when patients with mitral valve disease (in the absence of prosthetic repair or replacement) undergo dental or other invasive procedures that produce significant bacteremia with organisms associated with endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MITRAL VALVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two issues must be addressed when considering mitral valve surgery in patients with chronic MR: the indications for intervention; and the choice of procedure. These issues are discussed in detail separately but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This discussion will be limited to chronic MR due to primary valve disease. The management of functional and ischemic MR is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with severe chronic MR, surgery is indicated in patients with symptoms and in asymptomatic patients with abnormalities in LV size or function, pulmonary hypertension, or new onset atrial fibrillation (",
"    <a class=\"graphic graphic_algorithm graphicRef58148 graphicRef81099 \" href=\"UTD.htm?0/47/753\">",
"     algorithm 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51845 graphicRef71650 \" href=\"UTD.htm?23/21/23901\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgery may also be reasonable in asymptomatic patients with preserved left ventricular function if mitral valve repair is performed in experienced centers and it is estimated that the likelihood of successful repair without residual MR is greater than 90 percent.",
"   </p>",
"   <p>",
"    Asymptomatic patients with severe chronic MR who do not meet criteria for intervention can be safely treated with watchful waiting as long as the patient is carefully monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/25\">",
"     25",
"    </a>",
"    ]. Such patients should be seen every 6 to 12 months or sooner if symptoms occur. Repeat transthoracic echocardiography should be obtained at these visits. The six month interval is preferred if stability has not been documented, there is evidence of progression, or measurements are close to the echocardiographic cutoff values for mitral valve surgery (",
"    <a class=\"graphic graphic_table graphicRef68474 \" href=\"UTD.htm?3/34/3628\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Serial monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgery may be offered early in patients with borderline values for LV size or function in whom access to such monitoring is limited. On the other hand, a somewhat higher threshold for surgery is used if valve replacement is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link&amp;anchor=H9#H9\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\", section on 'Outcomes with watchful waiting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Mitral valve replacement versus repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two surgical procedures confined to the mitral valve itself are available for the treatment of chronic MR: valve repair and valve replacement. The choice of procedure depends, at least in part, upon the cause of the MR, the anatomy of the mitral valve, and the degree of left ventricular dysfunction.",
"   </p>",
"   <p>",
"    In most patients, mitral valve repair at experienced surgical centers is the preferred approach because of both functional and survival benefits compared to valve replacement (",
"    <a class=\"graphic graphic_figure graphicRef56177 \" href=\"UTD.htm?40/56/41869\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Valve repair versus valve replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When required, mitral valve replacement can be performed with a mechanical or bioprosthetic valve. Mechanical valves have the disadvantage of requiring lifelong",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, while bioprosthetic valves have the disadvantage of limited durability due to valve degeneration, particularly in patients under age 65. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When valve replacement is necessary, the following recommendations for the selection of a bioprosthetic or mechanical mitral valve were made by the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines when valve replacement (",
"    <a class=\"graphic graphic_table graphicRef75650 \" href=\"UTD.htm?28/61/29659\">",
"     table 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bioprosthetic valves are recommended in patients who cannot or will not take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or have a clear contraindication to warfarin therapy.",
"     </li>",
"     <li>",
"      Among patients who can take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , the weight of evidence supports the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A mechanical valve in patients under age 65 who have long-standing AF.",
"     </li>",
"     <li>",
"      A bioprosthetic valve in patients &ge;65 years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients under age 65 who are in sinus rhythm, patient preference plays a central role in the choice of valve. The guidelines suggested that a bioprosthetic valve should only be considered after a detailed discussion with the patient of the risks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy compared to the likelihood of repeat valve replacement in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Concurrent coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with nonischemic chronic MR requiring surgery also have significant coronary artery disease. Obstructive coronary lesions are usually revascularized at the time of mitral valve surgery, since concurrent bypass surgery typically adds little morbidity or mortality to the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]. A separate issue, which is discussed elsewhere, is the management of ischemic mitral regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assuming that the patient is not severely hemodynamically unstable, coronary angiography was recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines in patients who have or are suspected to have coronary disease (and who may have ischemic MR) and in those at risk for coronary disease (",
"    <a class=\"graphic graphic_table graphicRef66360 \" href=\"UTD.htm?29/4/29772\">",
"     table 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"     1",
"    </a>",
"    ]. At risk was defined as men &ge;35 years of age, women &ge;35 years of age with coronary risk factors, and postmenopausal women. A higher age threshold of &ge;45 years was recommended in patients without ischemic symptoms or coronary risk factors in whom MR is due to mitral valve prolapse because of a very low rate of significant coronary disease in younger patients with mitral valve prolapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical procedures for severe chronic mitral regurgitation\", section on 'Predicting coronary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Exercise after valve repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of exercise in patients with repaired mitral valves has not been well studied. The 36th Bethesda conference cited above recommended that such patients should not participate in sports that are associated with a risk of bodily contact or trauma that might disrupt the repair [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/16\">",
"     16",
"    </a>",
"    ]. They can participate in low-intensity competitive sports (class IA) and selected patients can participate in low and moderate static and low and moderate dynamic competitive sports (class IA, IB, and IIA) (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22872103\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods for percutaneous mitral valve repair to treat MR are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/26\">",
"     26",
"    </a>",
"    ]. Important questions will need to be addressed, such as relative efficacy compared to open repair and, if efficacy is less, how much less efficacy is acceptable compared to avoidance of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Techniques include direct and indirect annuloplasty approaches and an implantable clip. The MitraClip (Abbott Vascular) is a device that focally approximates the mitral leaflet edges. This device is commercially available in Europe, Israel and Australia but it is investigational in the United States.",
"   </p>",
"   <p>",
"    The efficacy of the MitraClip was studied in the EVEREST II trial, which enrolled 279 patients with chronic moderately severe or severe MR (grade 3+ or 4+) who were randomly assigned to undergo either percutaneous repair or mitral valve surgery (repair or replacement) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/51/33593/abstract/28\">",
"     28",
"    </a>",
"    ]. The primary efficacy endpoint was freedom from death, from surgery for mitral valve dysfunction, and from grade 3+ or 4+ MR at 12 months. The primary safety endpoint was a composite of major adverse events within 30 days. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower 12-month composite efficacy rate occurred in the percutaneous repair group compared to the surgical group (55 versus 73 percent). This difference was due to much more frequent subsequent surgery for mitral valve dysfunction in the percutaneous repair group (20 versus 2 percent). Death rates (6 percent for both) were similar in the two groups. Among patients evaluated for MR at 12 months, at least moderate (2+) MR was present in 46 percent in the percutaneous group and in 17 percent in the surgery group.",
"     </li>",
"     <li>",
"      At 12 months, both groups had improved New York Heart Association functional class, quality of life measures, and left ventricular size compared with baseline.",
"     </li>",
"     <li>",
"      Major adverse events at 30 days were significantly less common in the percutaneous repair group (15 versus 48 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the MitraClip provides a noninvasive means of mitral valve repair, but its efficacy in reducing mitral regurgitation is somewhat limited.",
"   </p>",
"   <p>",
"    The possible role of percutaneous mitral valve repair in chronic ischemic MR is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link&amp;anchor=H22#H22\">",
"     \"Ischemic mitral regurgitation\", section on 'Investigational approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=see_link\">",
"       \"Patient information: Mitral regurgitation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=see_link\">",
"       \"Patient information: Mitral regurgitation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5520719\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular (LV) chamber size and function have been used to define compensated, transitional, and decompensated stages in patients with chronic MR (",
"      <a class=\"graphic graphic_table graphicRef79918 \" href=\"UTD.htm?34/11/35003\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=see_link\">",
"       \"Pathophysiology and stages of chronic mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Indications for surgery for MR have been developed with the goal of performing corrective surgery during the transition from a compensated to decompensated stage of the disease (ie, before the decompensated stage is established). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Stages of MR'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic patients with flail leaflet and severe MR (as for other asymptomatic patients with severe MR), surgical correction should be considered early in the course of the disease if valve repair is feasible with a &gt;90 percent likelihood of success. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=see_link\">",
"       \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H24\">",
"       'Mitral valve surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic MR who become symptomatic are candidates for corrective mitral surgery, even if the symptoms improve with medical therapy or the left ventricle appears to be compensated (",
"      <a class=\"graphic graphic_table graphicRef51845 \" href=\"UTD.htm?34/19/35132\">",
"       table 2A",
"      </a>",
"      ). If there is uncertainty about the presence or absence of symptoms, exercise testing may provide objective information that may not be available from the medical history alone. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of MR is assessed semiquantitatively by Doppler echocardiography. Regardless of echo-Doppler grading, severe chronic MR does NOT exist (with rare exceptions) without clear evidence of left atrial or left ventricular enlargement. If the left ventricular end-diastolic dimension (by echocardiography) is less than 60 mm (approximately 35",
"      <span class=\"nowrap\">",
"       mm/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      the diagnosis of severe chronic MR should be seriously questioned. Left atrial size may reflect the \"history\" (severity and duration) of chronic MR, (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial echocardiographic monitoring is indicated in patients with mitral regurgitation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Serial monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While atrial fibrillation is not an absolute indication for surgery in an asymptomatic patient with preserved left ventricular function, the burden of this arrhythmia in a patient with borderline left ventricular function (LVEF 55 to 60 percent) may be considered as an indication for surgery, especially if the risk of surgery is low and the valve appears to be amenable to repair. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Mitral valve replacement versus repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for vasodilator therapy in patients with chronic MR depend upon the presence or absence of symptoms and the functional state of the left ventricle. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Use of vasodilators'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=see_link\">",
"       \"Vasodilator therapy in chronic mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Two issues must be addressed when considering mitral valve surgery in patients with chronic MR: the indications for intervention and the choice of procedure. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Mitral valve surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=see_link\">",
"       \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=see_link\">",
"       \"Surgical procedures for severe chronic mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/1\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/2\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/3\">",
"      Schuler G, Peterson KL, Johnson A, et al. Temporal response of left ventricular performance to mitral valve surgery. Circulation 1979; 59:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/4\">",
"      Zile MR, Gaasch WH, Carroll JD, Levine HJ. Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress. J Am Coll Cardiol 1984; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/5\">",
"      Wisenbaugh T, Skudicky D, Sareli P. Prediction of outcome after valve replacement for rheumatic mitral regurgitation in the era of chordal preservation. Circulation 1994; 89:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/6\">",
"      Borow KM, Green LH, Mann T, et al. End-systolic volume as a predictor of postoperative left ventricular performance in volume overload from valvular regurgitation. Am J Med 1980; 68:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/7\">",
"      Carabello BA, Nolan SP, McGuire LB. Assessment of preoperative left ventricular function in patients with mitral regurgitation: value of the end-systolic wall stress-end-systolic volume ratio. Circulation 1981; 64:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/8\">",
"      Crawford MH, Souchek J, Oprian CA, et al. Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation 1990; 81:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/9\">",
"      Ross J Jr. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J Am Coll Cardiol 1985; 5:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/10\">",
"      Dujardin KS, Enriquez-Sarano M, Bailey KR, et al. Grading of mitral regurgitation by quantitative Doppler echocardiography: calibration by left ventricular angiography in routine clinical practice. Circulation 1997; 96:3409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/11\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/12\">",
"      Reed D, Abbott RD, Smucker ML, Kaul S. Prediction of outcome after mitral valve replacement in patients with symptomatic chronic mitral regurgitation. The importance of left atrial size. Circulation 1991; 84:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/13\">",
"      Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005; 111:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/14\">",
"      Yusoff R, Clayton N, Keevil B, et al. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol 2006; 97:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/15\">",
"      Klaar U, Gabriel H, Bergler-Klein J, et al. Prognostic value of serial B-type natriuretic peptide measurement in asymptomatic organic mitral regurgitation. Eur J Heart Fail 2011; 13:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/16\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/17\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"    <li>",
"     Betriu A, Chaitman BR, Almazan A. Preoperative determinants of return to sinus rhythm after valve replacement. In: Cardiac Bioprosthesis, Cohn LH, Gallucci V (Eds), York Medical, New York 1982. p.184.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/19\">",
"      Flugelman MY, Hasin Y, Katznelson N, et al. Restoration and maintenance of sinus rhythm after mitral valve surgery for mitral stenosis. Am J Cardiol 1984; 54:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/20\">",
"      Greenberg BH, DeMots H, Murphy E, Rahimtoola SH. Arterial dilators in mitral regurgitation: effects on rest and exercise hemodynamics and long-term clinical follow-up. Circulation 1982; 65:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/21\">",
"      Sch&ouml;n HR, Schr&ouml;ter G, Barthel P, Sch&ouml;mig A. Quinapril therapy in patients with chronic mitral regurgitation. J Heart Valve Dis 1994; 3:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/22\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/24\">",
"      Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/25\">",
"      Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006; 113:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/26\">",
"      Feldman T, Cilingiroglu M. Percutaneous leaflet repair and annuloplasty for mitral regurgitation. J Am Coll Cardiol 2011; 57:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/27\">",
"      Block PC. Percutaneous mitral valve repair: are they changing the guard? Circulation 2005; 111:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/51/33593/abstract/28\">",
"      Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364:1395.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8132 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33593=[""].join("\n");
var outline_f32_51_33593=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5520719\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stages of MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Etiology of mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - MR due to flail leaflet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION OF MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Serial monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14009091\">",
"      Natriuretic peptide levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PHYSICAL ACTIVITY AND EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ATRIAL ENLARGEMENT AND FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Left atrial enlargement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      USE OF VASODILATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CARDIAC RESYNCHRONIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rheumatic mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nonrheumatic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MITRAL VALVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Mitral valve replacement versus repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Concurrent coronary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Exercise after valve repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22872103\">",
"      PERCUTANEOUS REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5520719\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8132|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/39/10879\" title=\"algorithm 1A\">",
"      Rx asymptomatic chron severe MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?13/36/13902\" title=\"algorithm 1B\">",
"      Rx symptomatic chron severe MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8132|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/56/41869\" title=\"figure 2\">",
"      NYHA repair vs replacement MV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/11/35003\" title=\"table 1\">",
"      Echo stages of chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/19/35132\" title=\"table 2A\">",
"      Valve surgery nonischemic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/34/31275\" title=\"table 2B\">",
"      Valve surgery congenital MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/34/3628\" title=\"table 3\">",
"      TTE in chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/15/30971\" title=\"table 4\">",
"      TEE in chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/46/35564\" title=\"table 5\">",
"      Severity of MR in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/11/38075\" title=\"table 6\">",
"      Cardiac cath chronic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29659\" title=\"table 7\">",
"      ACC AHA selection mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/4/29772\" title=\"table 8\">",
"      Coronary angio valve disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=related_link\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/37/2648?source=related_link\">",
"      Nonarrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/2/36901?source=related_link\">",
"      Pathophysiology and stages of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/59/27575?source=related_link\">",
"      Patient information: Mitral regurgitation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/60/19394?source=related_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36697?source=related_link\">",
"      Surgical procedures for severe chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29109?source=related_link\">",
"      Vasodilator therapy in chronic mitral regurgitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_51_33594="Fixed drug eruption dark skin";
var content_f32_51_33594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86671%7EDERM%2F52192%7EDERM%2F73678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86671%7EDERM%2F52192%7EDERM%2F73678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On dark skin, fixed drug eruption presents as a dark brown/slate-gray patch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruption. An oval lesion occurred at the identical site where it had occurred previously. In both episodes, the rash emerged after this patient ingested a sulfonamide antibiotic. Note the eroded blister in the center of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fixed drug eruptions (A) typically resolve with postinflammatory hyperpigmentation (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Chris Ha, MD, DermAtlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33594=[""].join("\n");
var outline_f32_51_33594=null;
var title_f32_51_33595="Hypercoagulability in IBD";
var content_f32_51_33595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypercoagulability in inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Clinical characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unusual sites",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Associated with active disease and better when disease controlled",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Associated with use of steroids (possibly indicating active disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serious",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Younger age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Abnormalities described",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal fibrinolysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal platelet aggregation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Activated protein C increased",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Circulating immune complexes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased antithrombin III",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Factor V Leiden mutation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased cytokines (interleukin-6, thrombopoietin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased factors V and VIII",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased plasminogen activator inhibitor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased sedimentation rate, fibrinogen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lupus anticoagulant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thrombocytosis and leukocytosis (uniformly present in most studies)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33595=[""].join("\n");
var outline_f32_51_33595=null;
var title_f32_51_33596="Opioid analgesics for use in children";
var content_f32_51_33596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opioid analgesics for use in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Equianalgesic dose*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Oral dose and frequency",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        IV dose and frequency",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Oral",
"        <br/>",
"        (mg)",
"       </td>",
"       <td class=\"subtitle2\">",
"        IV",
"        <br/>",
"        (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.3 mg/kg every three to four hours",
"       </td>",
"       <td>",
"        0.1 mg/kg every two to four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydromorphone",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.04 to 0.06 mg/kg every three to four hours",
"       </td>",
"       <td>",
"        0.015 mg/kg every two to four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        0.1 to 0.2 mg/kg every three to four hours",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        0.1 (100 mcg)",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        0.5 to 1 mcg/kg every one to two hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        0.1 mg/kg every eight to twelve hours",
"       </td>",
"       <td>",
"        0.05 to 0.1 mg/kg every eight to twelve hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tramadol*",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        &ge;4 years of age: 1 to 2 mg/kg every four to six hours",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     N/A: not available.",
"     <br/>",
"     * Approximate equianalgesic dose for estimation when changing opioid agents. Role of tramadol is limited to treatment of moderate pain in children. Effect may not be equivalent to 3 mg oral morphine.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Doses are for individuals over 6 months of age with a maximum weight of 50 kg. Oral doses refer to immediate release products.",
"     <br/>",
"     &Delta; Dose adjustment for renal insufficiency may be required. Not recommended in severe renal insufficiency.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Due to gradual drug accumulation at tissue sites, the dose and frequency of methadone differs for initial compared with repeated use; dose and interval given is usual after repeated use; methadone should be initiated and titrated by a clinician experienced with its use.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gutstein HB, Akil H. Opioid analgesics. In: Goodman &amp; Gilmans pharmacological basis of therapeutics, 11th ed, McGraw-Hill, New York 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33596=[""].join("\n");
var outline_f32_51_33596=null;
var title_f32_51_33597="Probability of HP";
var content_f32_51_33597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61899&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical probability of hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Exposure to a known offending antigen",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Recurrent episodes of symptoms",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Symptoms 4-8 h after exposure",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Weight loss",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        Crackles, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        (+) Serum precipitins",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        (-) Serum precipitins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        +",
"       </td>",
"       <td class=\"subtitle3\">",
"        -",
"       </td>",
"       <td class=\"subtitle3\">",
"        +",
"       </td>",
"       <td class=\"subtitle3\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All the predictors are dichotomous variables.",
"    <div class=\"footnotes\">",
"     -: absent; +: present.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lacasse, Y, Selman, M, Costabel, U, et al. Diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003; 168:952. Copyright &copy; 2003 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33597=[""].join("\n");
var outline_f32_51_33597=null;
var title_f32_51_33598="Thumbprinting C difficile";
var content_f32_51_33598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumbprinting in pseudomembranous colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 208px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain film of the abdomen demonstrates marked thickening of the wall of the ascending colon (arrows), producing a thumbprinting pattern. This appearance is seen in all forms of colitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33598=[""].join("\n");
var outline_f32_51_33598=null;
var title_f32_51_33599="Chronic lung melioidosis";
var content_f32_51_33599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of chronic pulmonary melioidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic melioidosis in the lung mimicking tuberculosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_51_33599=[""].join("\n");
var outline_f32_51_33599=null;
